Expression and regulation of liver regeneration associated protein ALR under patho-physiological conditions by Dayoub, Rania
 Expression and Regulation of liver regeneration associated 
protein ALR under patho-physiological conditions 
 
 
 
Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften 
(Dr. rer. nat) 
an der Fakultät für Chemie und Pharmazie 
der Universität Regensburg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vorgelegt von 
Rania Dayoub 
aus 
Damaskus-SYRIEN 
Regensburg im Juli 2009
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work presented in this thesis was carried out at the Center of Liver Cell 
Research, Department of Surgery at the University Hospital Regensburg from 
January 2005 to March 2009 under the supervision of PD Dr. Thomas. S. Weiß. 
Die vorliegende Arbeit entstand unter der Anleitung von PD Dr. Thomas. S. Weiß in 
der Zeit von Januar 2005 bis März 2009 am Zentrum für Leberzellforschung, Klinik 
und Poliklinik für Chirurgie, Klinikum der Universität Regensburg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date of colloquium:   07.08.2009 
Board of examiners:    Chairman: Prof. Dr. Hubert Motschmann 
First Examiner: Prof. Dr. Armin Buschauer 
Second Examiner: PD Dr. Thomas. S. Weiß 
Third Examiner: Prof. Dr. Jörg Heilmann 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Life is not about finding yourself. Life is about creating yourself.” 
 
George Bernard Shaw (1856-1950) 
Irish dramatist and nobel prize winner for literature in 1925. 
 
 
Acknowledgements 
 
I would like to express my thanks and appreciations to many people for contributing 
for the Happy End of my PhD thesis: 
I would like to thank Prof. Dr. Hans Jürgen Schlitt for taking me as a PhD student and 
for his truly generous support during all those years. 
Special thanks go to Prof. Dr. Armin Buschauer, my supervisor at the Faculty of 
Pharmacy at Regensburg University for accepting to supervise and review my thesis. 
I would like to express my deepest sense of gratitude to PD Dr. Thomas S Weiß for 
his continuous guidance, encouragement and excellent advice throughout this study 
and for always saying “Carpe diem”. 
I would like to thank my colleagues in the lab; Katja Müller, Anja Gräbe, Brigitta 
Hauer and Stefan Kirchner for the wonderful atmosphere, for making me feel at 
home and for sharing various thoughts during the “coffee break” in the late afternoon. 
Many thanks to Sabine Laberer for our culinary events, for your precious friendship 
and endless patience and for always reminding me that “alles wird gut”. 
I am grateful to Dr. Thilo Spruss and his lab for their BIG help in doing the 
xenotransplantation-experiments and microscopy. 
I would like to thank Prof. Dr. Anja Bosserhoff for her precious tips in performing the 
promoter studies. 
Many thanks to PD Dr. Claus Hellerbrand and his lab for performing and providing 
me the hepatic fibrosis models. 
Special thanks to Prof. Dr. Oliver Stölzing, Dr. Christina Hackl and their assistant 
Christine Wagner for providing me the CCl4-model samples and for performing the 
migration and invasion assays. 
I thank Prof. Dr. Thomas Dobner and Peter Groitl for providing me the backbone 
vectors and for their help and advices in designing the targeting vectors. 
 Not to forget the whole Forschungsbau H4 where I could find all I needed during the 
course of this work. In detail, to Dr. Elke Eggenhoffer and to Gabriela Schiechl for our 
long conversations, to Irina Kucuk for her delicious russian specialities. 
I am tremendously grateful to my family for accepting me being so far for so long. My 
Father, Prof. Dr. Faysal Dayoub, in the first place is the person who put the 
fundament my learning character, showing me the joy of intellectual pursuit ever 
since I was a child. My Mother, Faten, is the one who sincerely raised me with her 
caring and endless love. This work should serve as a small token for your (continued) 
belief in my head. 
Mazen, Dima and Tarek, thanks for being supportive and caring siblings. Your love is 
deeply cherished and will always be needed! 
I am particularly grateful to Rima Ghamrawi for helping me whenever I felt the need 
to escape reality! for your infinite patience and for believing in me even in the 
moments I doubted myself! Thank you. 
Finally, I would like to thank everybody who was important to the successful 
realization of thesis, as well as expressing my apology that I could not mention 
personally one by one. 
Table of contents 
 
I. INTRODUCTION .................................................................................................1 
1. The liver ................................................................................................................3 
2. Liver regeneration .................................................................................................3 
3. Augmenter of Liver Regeneration (ALR)...............................................................7 
3.1. ALR and mitogenic growth............................................................................7 
3.2. ERV1/ALR family..........................................................................................7 
3.3. ALR and protein biogenesis........................................................................11 
3.4. ALR and liver regeneration .........................................................................12 
3.5. ALR promoter and its regulation .................................................................18 
4. Liver-Enriched Transcription Factors/LETF ........................................................19 
II.  AIM OF THE THESIS ....................................................................................21 
III. MATERIALS & METHODS ..........................................................................25 
1. Materials .............................................................................................................27 
1.1. Reagents, Chemicals, Kits, Solutions.........................................................27 
1.2. Oligonucleotides .........................................................................................32 
1.3. Technical equipment ..................................................................................33 
1.4. Databases research ...................................................................................34 
2. Methods ..............................................................................................................35 
2.1. Primary cells and cell lines .........................................................................35 
2.1.1. Isolation of primary human hepatocytes.............................................35 
2.1.2. Cultivation of hepatocytes and cell lines.............................................35 
2.1.3. Stimulation and treatment of cells ......................................................36 
2.1.4. Transfection of cell lines.....................................................................37 
 2.1.5. Migration and invasion assays ...........................................................39 
2.2. Protein biochemical methods......................................................................39 
2.2.1. Preparation of cell protein extracts from mammalian cells .................39 
2.2.2. SDS-Polyacrylamid-gel electrophoresis (SDS-PAGE) .......................40 
2.2.3. Western Blot analysis.........................................................................41 
2.2.4. Immunohistochemistry (IHC)..............................................................42 
2.3. Nucleic acid methods .................................................................................42 
2.3.1. RNA-related methods.........................................................................42 
2.3.1.1. RNA isolation, reverse transcription and cDNA synthesis..........42 
2.3.1.2. Polymerase chain reaction (PCR)..............................................43 
2.3.1.3. Real-time polymerase chain reaction (RT-PCR)........................45 
2.3.2. DNA-related methods.........................................................................45 
2.3.2.1. Molecular cloning .......................................................................45 
2.3.2.2. DNA sequencing and sequence analysis...................................47 
2.3.2.3. Electrophoretic mobility shift assay (EMSA) ..............................47 
2.4. Bacterial culture..........................................................................................48 
2.5. Animal models ............................................................................................49 
IV. RESULTS.........................................................................................................51 
1. Analysis of ALR expression ................................................................................53 
1.1. Expression of ALR in regenerating livers....................................................53 
1.2. Expression of ALR in parenchymal liver cells .............................................55 
1.3. Expression of ALR in human HCC tissues .................................................56 
2. Regulation of ALR expression.............................................................................57 
2.1. Liver specific cytokines and growth factors.................................................57
2.2. Analysis of ALR promoter: Putative transcription factor binding sites.........59 
2.3. Impact of FOXA2 on ALR expression.........................................................62 
2.4. Effect of IL-6 RE-BP and C/EBPβ on ALR promoter activity ......................66 
2.5. Synergistic effect of FOXA2 and IL-6 on ALR promoter .............................67 
3. Overexpression of ALR.......................................................................................70 
3.1. Generation of ALR-overexpressing HepG2 cells ........................................70 
3.2. Tumorgenicity of ALR-overexpressing HepG2 cells ...................................72 
3.3. Impact of ALR on migration and invasiveness of hepatoma cells...............76 
3.4. Effect of ALR on EMT markers ...................................................................79 
V.  DISCUSSION ..................................................................................................83 
VI. SUMMARY.......................................................................................................95 
REFERENCES ......................................................................................................99 
ABBREVIATIONS ..............................................................................................127 
APPENDIX ...........................................................................................................133 
PUBLICATIONS AND PRESENTATIONS ..................................................137 
EIDESSTATTLICHE ERKLÄRUNG ..............................................................141 

I. Introduction 
 
1
 
 
 
 
 
 
 
 
 
 
 
I. INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I. Introduction 
 
3
1. The liver 
The liver is an important and life-saving organ, which is one of the biggest glands in 
the human body. It plays a central role in regulating the metabolic homeostasis which 
includes synthesis, storage and secretion of different molecules such as 
carbohydrates, fats and vitamins. It fulfils a main task in detoxification and removes 
toxic substances by metabolic conversion and biliary excretion. Furthermore, the liver 
is responsible for the biotransformation of endogenous substances such as bilirubin, 
bile acids and hormones, as well as exogenous substances like xenobiotics and 
alcohol. The liver is composed of different cell types, which are summarized as 
parenchymal and non-parenchymal cells (NPC). Hepatocytes as well as 
cholangiocytes belong to parenchymal cells and hepatocytes, which are the main cell 
type compose up to 80% of the liver cells and carry out most of the liver functions. 
Non-parenchymal cells include endothelial cells, Kupffer cells, stellate cells and cells 
from the blood compartment. Endothelial cells compose the circulatory blood vessels 
and form the walls of the hepatic sinusoids. Kupffer cells, liver-specific macrophages, 
are essential for the phagocytosis of foreign organisms in the liver and represent 
beside the stellate cells, the main source of cytokines and inflammatory factors 1. 
Lymphocytes play an important role for innate immunity and defense against 
infection in the liver. Stellate cells -also termed Ito cells- have different functions e.g. 
they serve as fat and vitamin A-storage cells and produce most of the extracellular 
matrix (ECM) proteins 1. 
2. Liver regeneration 
The liver has an extraordinary capacity to regenerate after injury and this ability 
protects animals and humans from liver failure caused by infections or toxins. The 
ancient Greeks were among the first who described the hepatic regeneration as 
“ever-regenerating liver” in the myth of Prometheus’ 2. It was told that Zeus punished 
the Titan Prometheus for stealing the fire and giving it to man. He was chained on the 
top of Mt. Caucasus, where an eagle ate daily from his liver. As an immortal Titan, 
Prometheus’ liver constantly regrew during the night, making the torment endless 3 
(Fig. 1). 
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Fig. 1: A statue representing the torment of Prometheus. The picture was taken at the Jardin 
des Tuileries, Paris (S.P.) 3. 
As mythical as the story is, but this describtion of an observation is based on the 
ability of the liver to renew. To date, the explanation of this phenomen has been in 
the focus of many researchers 4. The word “regeneration” means the ability of an 
organ to replace tissue mass after partial removal or injury 5,6. The process of liver 
regeneration is a multistep and well-orchestrated process which is initiated by liver 
injury such as physical damage (hepatectomy), infectious or toxic injury. This 
regenerative capacity is based on the ability of hepatocytes to proliferate in a 
differentiated state. Under normal conditions, hepatocytes are quiescent and rarely 
replicate in normal healthy livers 2,6-8. But after damage, the resulting metabolic 
overload activates hepatic cells to initiate signals towards hepatocytes for entering 
the cell cycle. This process begins with DNA replication in the parenchymal cells 
reaching a peak after 24 hours, followed by proliferation of the non-parenchymal cells 
which usually starts with a delay of one day 1,9,10. 
The hepatic regeneration consists of two major steps. First, priming which represents 
the transition of G0 to G1 and second, progression represented by the transition of 
G1 to S 7 (Fig. 2). After partial hepatectomy, released cytokines and/or circulating 
endotoxin (LPS) activate the non-parenchymal cells especially Kupffer cells 
stimulating them to produce tumor necrosis factor (TNF-α), interleukin IL-1 and IL-6. 
These factors stimulate hepatocytes enabling them for entering into G1-phase 
(Fig. 2). While hepatocytes undergo transition from G0 to G1, a large number of 
genes are either enhanced or de novo expressed. The first state of gene expression, 
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also termed immediate early phase, occurs within 4 h after injury and is identified by 
increased expression of protooncogenes such as c-fos, c-jun and c-myc (Fig. 2). 
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Fig. 2: Liver regeneration is triggered by liver damage such as partial hepatectomy 11. 
After reaching the G1-phase, hepatocytes are able to respond to a wide variety of 
mitogens such as HGF, EGF, TGF-α and ALR, or to co-mitogens such as insulin 11,12. 
The mitogenic factors have been shown to stimulate hepatocytes to pass the 
restriction point -also termed cell cycle checkpoint- and to enter the cell cycle 
followed by DNA synthesis 13-15. This progression phase is accompanied by 
increased expression of the so-called “delayed early genes”. The transcription of 
these genes such as bcl-x and FoxM1B is followed by cell cycle progression which is 
associated with enhanced expression of the cell cycle genes e.g. p53, p21, mdm-2, 
cyclines and cyclin dependent kinases. The p53 and p21 are cell cycle inhibitors, 
while mdm-2 and cyclin D1 stimulate DNA replication 11 (Fig. 2). Once the liver 
reaches its requisite original mass, hepatocytes stop to divide and return to the non-
proliferative state. The termination of this process requires different factors, and the 
most well-known hepatocyte anti-proliferative factor is TGF-β, which is released from 
stellate cells. TGF-β is blocked during the proliferative phase but is restored when 
I. Introduction 
 
6 
regeneration is completed, and this restoration of TGF-β inhibits DNA synthesis and 
supports hepatocytes to re-enter the quiescent state 1. 
Growth factors implicated in regulating liver regeneration could be divided into two 
main classes namely complete mitogens and incomplete mitogens, also named 
co-mitogens. Complete mitogens are growth factors which can stimulate hepatocyte 
replication in vitro in the absence of other factors. These include HGF, EGF, TGF-α 
and ALR which are released from stellate cells, duodenum and hepatocytes, 
respectively (Fig. 3). 
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Fig. 3: Cytokines, growth factors and co-mitogens involved in liver regeneration 2,16. 
In contrast, co-mitogens secreted from the pancreas (insulin), adrenal gland 
(norepinephrine) and thyroid gland (triiodothronine; T3) are factors which augment 
the effect of complete mitogens in vitro, but have no effect alone on hepatocyte 
replication 11,12,17 (Fig. 3). 
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3. Augmenter of liver regeneration (ALR) 
3.1. ALR and mitogenic growth 
Early studies have focused on the quest of factors involved in liver regeneration and 
possibly exerting a pro-proliferative effect on hepatocytes. 1975, LaBrecque and 
Pesch first isolated an extract called hepatic stimulator substance (HSS) from 
weanling and regenerating rat livers 18. This factor was first discovered in the cytosol 
of parenchymal cells in the liver 18-20, and was reported to stimulate the cellular 
proliferation in hepatectomized livers of rats 18 and dogs 19,20. Later, the purified 
peptide from the extract HSS has been sequenced, the isolated protein renamed 
ALR 21,22, and the rat, mouse and human ALR gene was cloned 23,24. Augmenter of 
liver regeneration (ALR, also known as Hepatopoietin, HPO), a heat-stable 
hepatotrophic growth factor, different from other growth factors is organ specific, but 
species non-specific 25. 
Unlike other common well-known growth factors such as EGF, HGF and TGF-α, 
which can stimulate the proliferation of different cell types 7, ALR has a specific 
proliferative action on the liver 26. This specific hepatic effect of ALR is due to the 
existence of a high affinity ALR receptor on the surface of primary hepatocytes and 
hepatoma cells 27. This receptor could not be detected on the membrane of other cell 
types like kidney, lung, ovary, larynx and hematopoietic tissue cell lines 27. Although 
ALR has been originally described as a factor which exerts its effect only on hepatic 
cells, it is expressed in a wide variety of different tissues. It has been found in kidney, 
brain, cerebellum and the highest expression was observed in testis and liver 23,24,28. 
3.2. ERV1/ALR family 
ALR belongs to a new protein family named ERV1/ALR (Family ID: F00004892). This 
family includes members which are represented in different organisms, including 
plants 29, prokaryocytes (except in bacteria) as well as in lower and higher 
eukaryotes.  
1996 Giorda et al. could isolate the human ALR cDNA (Gene ID: 2671) and reported 
the amino acid sequence of human ALR and its alignment with the rat and mouse 
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sequences 24. Human ALR gene has been mapped next to the polycystic kidney 
disease gene (PKD1) on chromosome 16 30. Analysis of human ALR genomic DNA 
revealed that it consists of three exons and two introns. The longest hALR transcript 
encodes for a 205 amino acid protein corresponding to a molecular weight of 
23 kDa 31, whereas the smallest hALR transcript encodes a protein of 125 amino acid 
(15 kDa) 32,33, which lacked the N-terminal 80 amino acids 31. Since the 15 kDa 
isoform of hALR protein does not contain any known leader-sequence, it is mainly 
located in the cytosol and also found in the nucleus 34. In contrary and under normal 
conditions, the full-length hALR is mainly located in the mitochondrial intermembrane 
space (IMS) 35. Both forms of the human ALR protein were found to be present in 
hepatocytes, and these two spliced forms of ALR are able to dimerize which allows 
hALR protein to exist as a dimer. In addition, it has been shown that hALR gene 
could be alternatively spliced at the transcriptional level, that means that both 
isoforms are synthesized from the same mRNA using different initiation codes 34. 
Figure 4 shows the sequence alignment and conserved amino acids of the full length 
rat, mouse and human ALR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Sequence alignment of the full length rat (r), mouse (m) and human (h) ALR. Identical 
amino acids found at the same position in all three proteins are shown in the conservation 
line. Dashes indicate absence of the base. The first 70 amino acids show significantly less 
conserved amino acid residues than the rest of the protein sequences. Arrows mark the 
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methionine residues of both long and short form of ALR. The sequences of rALR 
(EDM03859), mALR (NP_075527) and hALR (NP_005253) were obtained from Pubmed 
search tool. 
The three-dimensional structure of human ALR protein has been examined by 
Farrell et al., and is shown in Fig. 5B. Subunit A is shown in blue and subunit B in 
gray (with N- and C-termini highlighted in green). Cysteine residues are numbered 
and shown in yellow, and the FAD is in orange. The second disulfide bridge 
(C91-C108), shown in Fig. 5A, is conserved between ERV1, ERV2 and mammalian 
ALR 36. The third disulfide bond forms intersubunit links (C15-C124) between the 
N- and C- termini of ALR 36. These two intersubunit disulfide bonds are unique to 
ALR, they have not been found in ERV1 and ERV2. 
 
 
A B
Fig. 5: A) Proposed thiol/disulfide pattern in human ALR. ALR is a disulfide bridged dimer 
(linked via C15−C124) with two free cysteine residues (C74 and C85) per monomer, and 
these free cysteines are not essential for enzymatic activity toward DTT, consistent with their 
lack of conservation between rat and human sequences. The C15−C124 disulfides are not 
critical for dimer formation and have insignificant impact on the dithiothreitol (DTT) oxidase 
activity of ALR. Cytochrome c is about a 100-fold better electron acceptor for ALR than 
oxygen when DTT is the reducing substrate. B) Homology model of human short-form ALR 
(125 amino acids) based on the crystal structure of rat ALR. The FAD in subunit B is omitted, 
and only C15 (B) and C124 (B) are depicted 37. 
Each 15 kDa isoform of human ALR contains two additional nonconserved free 
cysteine residues (C74 and C85) depicted in Fig. 5A 37. Farrell et al. proposed that 
ALR may not necessarily function as a sulfhydryl oxidase in the mitochondrial 
intermembrane space but it may communicate with the respiratory chain via the 
mediation of cytochrome c 37 (Fig. 5). 
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Giorda et al. in 1996, first cloned and characterized the mouse ALR gene (Gene 
ID: 11692). They showed that mALR gene is comprised of three exons, and is 
mapped to the mouse chromosome 17. Furthermore, they have found that the 
function of mALR protein is not limited to liver regeneration, but it is also involved in 
the synthesis or stability of the nuclear and mitochondrial transcripts. In addition, 
mouse ALR has been found to be highly expressed in actively regenerating cells, 
particularly in hepatocytes of hepatectomized livers and in germ cells of the testis 24. 
The long form of mouse ALR protein shares extensive amino acid homology (79%) 
with the long form of human ALR protein (Fig. 4). 
Rat ALR (Gene ID: 27100) was first discovered by Hagiya et al. in 1994. They cloned 
and sequenced the rat ALR gene, which was considered to encode rat HSS 23. 
Furthermore, analysis of the rat genomic DNA of ALR revealed that the gene is 
composed of 3 exons and 2 introns and is 1508 nt long 38. The rat ALR protein, which 
consists of 125 amino acids (15 kDa), acts as a homodimer 23 and the long form of 
rat ALR protein (22 kDa) exhibits 77% homology to human ALR (Fig. 4). 
The ERV1/ALR family also includes ERV1 (Essential for Respiration and Vegetative 
growth) protein (scERV1) from Saccharomyces cerevisiae. The yeast scERV1 (Gene 
ID: 416547) was found to be essential for the viability of the cell, the cell cycle and 
the maintenance of intact mitochondrial genomes 39,40. It is involved in mitochondrial 
biogenesis, and this function lies on its enzymatic flavin-linked sulfhydryl oxidase 
activity 41-43. The most recent studies have focused on the function of ERV1 in the 
biogenesis of mitochondrial intermembrane space (IMS) proteins i.e. small 
Translocases of the Inner Membrane (TIMs). Translocation of these small proteins is 
performed via Translocase of Outer Membrane, the TOM complex. The TOM 
complex forms a channel which allows unfolded proteins to pass freely into the IMS, 
in both directions 44. This import is mediated primarily by the essential IMS protein 
Mia40, which plays an essential role in the folding of imported cysteine-rich 
precursors 45. It has been found that ERV1 is required for the import of the TIM 
proteins and it plays an important role for their biogenesis via interactions with Mia40. 
The latter oxidizes the newly imported proteins resulting in their final folded 
conformation. Subsequently, Mia40 is re-oxidized by direct interaction with ERV1 via 
thiol-disulfide exchange reactions 46,47. The fact that scERV1 is oxidized by 
cytochrome c in vivo prompted Allen et al. to conclude that scERV1 functionally links 
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the Mia40-dependent import pathway to the respiratory chain transferring electrons 
from incoming polypeptides to cytochrome c 48. The scERV1 has been found to 
exhibit 50% homology to the short form of rat ALR protein (15 kDa) 23. Analysis of the 
complete genome sequence from S. cerevisiae revealed a second gene with 30% 
similarity and structural homologies to ERV1. In addition, the newly discovered gene 
ERV2 is the first member of the ERV1/ALR protein family located in the microsomes. 
Different from the mitochondrial ERV1, ERV2 is located in endoplasmatic reticulum 
(ER) in yeast, contains a CXXC motif and exhibits a sulfhydryl oxidase activity 49-51. 
Recent studies in Drosophila melanogaster have shown that a gene (CG12534), 
orthologous to mammalian ALR may have a function during regeneration. Mutations 
in this gene affected the regeneration by either delaying, reducing or positioning the 
regeneration blastema. Based on these results, McClure et al. have proposed that 
CG12534 functions early in the regenerative proliferation and growth in 
drosophila 52,53. 
The vaccinia virus protein E10R belongs also to this family and plays a central role in 
the virus life cycle. It has been shown that E10R protein is associated with the 
intracellular mature virions and is required for virion morphogenesis 54,55. Another 
viral member of this family was found in African Swine Fever Virus (ASFV). ASFV 
encodes a protein termed 9GL which plays an essential role in viral growth in 
macrophages and viral virulence in swine 56. 
3.3. ALR and protein biogenesis 
Iron/sulfur (Fe/S) cluster-containing proteins are key players for electron transfer, 
metabolic and regulatory processes. Mitochondria in eukaryotes are one of the 
organelles responsible for protein biogenesis such as formation of Fe/S cluster 
proteins 51,57-59. Functional cytosolic and nuclear Fe/S proteins act as sensors of 
oxygen or reactive oxygen species and therefore important for regulation of oxygen-
responsive genes 60 and in the process of sperm development 28. 
In addition, the mitochondrial isoform of ALR protein (23 kDa) was found to be 
involved in the export of Fe/S clusters from the mitochondrial matrix 35. Furthermore, 
Lange et al. have found that ALR in the IMS is important for the assembly and 
biogenesis of cytosolic Fe/S proteins. Additionally, they have investigated which part 
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of the ALR protein is important for Fe/S protein assembly. Interestingly, it was found 
that the entire ALR protein (23 kDa) including the well-conserved C-terminus and the 
poorly conserved N-terminus is crucial for the assembly function. 
In addition, in the nervous system ALR might be of importance in metal ion 
homeostasis whose dysregulation can induce neurodegenerative disorders. The 
involvement of ALR in the function of brain could be explained by the fact that ALR 
plays an important role in the iron homeostasis 35 and might interact with 
metallothioneins (MTs) 61, which bind metal ions such as zinc and copper 62. 
A further reason for the involvement of ALR in the iron homeostasis is that 
mitochondrial iron overload can be a direct consequence of impaired iron/sulfur 
cluster assembly. Iron/sulfur proteins may serve as sensors of mitochondrial iron 
status and an inadequate iron/sulfur clusters impair the sensor function. A 
dysregulation of mitochondrial iron uptake as well as export may lead to iron 
overload 63. 
3.4. ALR and liver regeneration 
In the liver, ALR has been found to be constitutively expressed and stored 
exclusively in hepatic parenchymal cells 18-20. Tanigawa et al. have determined the 
ALR mRNA expression in hepatic tissues and ALR protein levels in blood samples. 
Interestingly, they found that hepatic ALR mRNA expression was higher in patients 
with liver disease than in healthy controls, and a correlation was observed between 
serum ALR values and hepatic levels of ALR mRNA. In addition, several 
studies 26,64-67 have been published reporting that ALR augments liver regeneration 
and this is mediated by different mechanisms. The following conceivable 
mechanisms have been suggested (Fig. 6): 
(i) activation of mitogen-activated protein kinase (MAPK) cascade through the 
induction of tyrosine phosphorylation of (EGF-R) 
(ii) regulation of AP-1 activity 
(iii) suppression of liver-resident natural killer (NK) cells. 
Ad (i), ALR augments liver regeneration by activation of MAPK in hepatic cells 
followed by activation of various transcription factors e.g. AP-1 and NF-кB. ALR binds 
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to its own specific surface receptor on the hepatocytes 27 and this binding results in 
phosphorylation of MAPK cascades 64. Therefore, ALR seems to resemble other 
growth factors e.g. EGF, HGF, TGF- α, which have similar mitogenic effect on 
hepatocytes via activation of MAPK pathway in a rapid and transient manner 7. 
Further, it has been shown that both MAPK activation and the mitogenic effect of 
ALR on hepatoma cells were completely blocked by a specific inhibitor of EGF-R 
tyrosine kinase activity but not by blocking EGF-R suggesting that tyrosine 
phosphorylation of EGF-R may be essential for ALR signal transduction 26 
(Fig. 6 and 9). In the same study, it was demonstrated that ALR has no effect on 
HGF receptor (c-met) 26. 
NK cells ALR
autocrine
Intracellular Extracellular 
AP-1MAPK 
Proliferation AP-1 and NF-кB
intracrine 
via JAB1 ALR-R & EGF-R 
 
Fig. 6: Schematic drawing demonstrating signaling pathways of ALR. While extracellular 
ALR activates the MAPK signaling pathway by binding to its specific receptor on hepatocytes 
and hepatoma cells, intracellular ALR activates AP-1 via JAB1 in MAPK-independent 
fashion 65. In addition, ALR augments the liver regeneration by supressing the NK cells 67,68. 
Ad (ii), ALR exerts its hepatotrophic effect on the liver by regulation of the activating 
protein-1 (AP-1). Intracellular ALR interacts with c-Jun activation domain-binding 
protein (JAB1) in vitro and in vivo triggering the transcriptional activity of AP-1 in a 
MAPK-independent manner 65 (Fig. 6). JAB1, the fifth subunit (CSN5, S5) of 
mammalian COP9 signalosome (CSN), is highly conserved from yeast to human 69. 
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JAB1, a co-activator of c-jun/AP-1 transcription factor, enhances binding of c-jun-
containing AP-1 complex to their DNA consensus sites and increases the 
transactivation of an AP-1 dependent promoter 70. Further, it was found that ALR 
colocalizes with JAB1 in the nucleus of hepatic cells 65. Interestingly, it has been 
hypothesized that the increased activation of AP-1 by ALR and JAB1 in COP9 
signalosome is due to the enhanced c-jun phosphorylation 65,71 (Fig. 9). ALR is the 
first intracrine hepatotrophic factor identified to trigger AP-1 cascade via intracellular 
interaction with a multicomponent protein regulator complex. This interaction 
suggests a possible linkage between CSN and liver regeneration 71. This might be a 
molecular link between the enzymatic redox function of ALR and its role as a factor 
with extracellular growth-promoting effect. It was shown that the cysteine residues 
(CXXC) in the C-terminus of ALR protein are necessary for the intracellular 
potentiation of AP-1 activity but not for the extracellular mitogenic effect of ALR 72. 
Based on this finding, they concluded that ALR induced AP-1 activity depends on 
sulfhydryl oxidase activity and therefore they hypothesized a redox regulation of 
COP9 signalosome by ALR. Taken together, hepatic parenchymal cells synthesize 
ALR which exerts its pro-proliferative effect as intracrine (via JAB1) as well as 
paracrine (via MAPK) factor. 
Ad (iii), ALR may augment liver regeneration by modulation of the lytic activity of 
natural killer (NK) cells. NK cells have been described as the major effector cells of 
nonadaptive immunity. Without prior antigen recognition, NK cells are able to mediate 
cytotoxicity against selected tumors and virus-infected cells 73,74. In addition, NK cells 
secret a wide variety of cytokines regulating the adaptive immune response against 
microbial infections 73-75. 
It has been shown that in vivo administration of ALR supress the hepatic NK 
cytotoxic activities in rats but do not affect the mononuclear leukocytes derived from 
spleen or peripheral blood 66 suggesting that ALR may be at least partially 
responsible for the local suppression of liver-resident NK cells 66. Tanigawa et al. 
have made the observation that in humans increased ALR blood levels parallels 
decreased NK cell activity 67. These data suggest that ALR may augment liver 
regeneration by local regulation of NK cells. Further, it was found that administration 
of ALR in healthy rats reduced the level of Interferon-γ (IFN-γ) in hepatic NK cells by 
suppressing the activity of NK cells. On the other hand, administration of IFN-γ in 
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70% hepatectomized rats led to significant reduction of both expression of 
mitochondrial transcription factor A (mt-TFA) and hepatic regeneration 68 (Fig. 7). 
Figure 7 summarizes results from Polimeno et al. 68 and shows that ALR exerts two 
effects, the first reduction of IFN-γ in hepatic NK cells leading to reduced cytotoxic 
activity of NK cells, whereas second induction of mt-TFA followed by upregulation of 
mitochondrial DNA (mt-DNA) expression and mitochondrial metabolism. Taken 
together, IFN-γ is one of the main mediators of ALR biological activity both as growth 
factor and immunoregulator 68. 
 
 
ALR IFN-γ
mt-TFA
NK lytic activity 
mt-DNA 
oxidative 
phosphorylation 
 
 
 
 
 
 
 
 
 
 
Fig. 7: ALR as immunoregulator and growth factor. The immunoregulatory effect of ALR is 
mediated by inhibition of IFN-γ expression followed by a strong decrease in NK cell lytic 
activities and by increase of hepatic mt-TFA which results in upregulation of mt-DNA and 
oxidative phosphorylation 68. 
In addition to the mitogenic effect of the hepatotrophic factor ALR, it was shown that 
ALR modulates the regulation of hepatic metabolism by repression of phase I 
reactions (Cytochrome P450) in human hepatocytes. In contrast, ALR had no effect 
on phase II reactions such as UGT activity and the GSH/GSSG ratio. Treatment of 
human hepatocytes with ALR downregulated basal and induced P450 activities, and 
this was due to increased activity of NF-кB and decreased expression of constitutive 
androstane receptor (CAR) 76. Based on these findings, it was suggested that ALR 
may have an effect which cross-links growth signals to regulation of hepatic 
metabolism 76 (Fig. 8). 
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Fig. 8: Repression of cytochrome P450 enzyme activity by ALR. ALR stimulates its receptor, 
and this stimulation leads to EGF receptor activation followed by induction of NF-кB activity. 
NF-кB activation is known to interact with glucocorticoid receptor (GR) resulting in reduction 
of CAR expression and altered P450 expression. In contrast, ALR has no effect on the 
expression of other orphan nuclear receptors like aryl hydrocarbon receptor (AhR) and 
pregnane X receptor (PXR) 76. 
Another hepatotrophic effect of ALR on the hepatic regeneration has been 
demonstrated by our group. We demonstrated that exogenously administered ALR 
was able to induce c-myc mRNA expression in primary human hepatocytes, resulting 
in elevated levels of ornithine decarboxylase (ODC) and S-adenosylmethionine 
decarboxylase, both key enzymes of polyamine biosynthesis 77. Polyamines, mainly 
putrescine, spermidine and spermine were considered essential molecules in several 
biological pathways like cell growth and differentiation 78,79. Treatment with ALR 
induced the expression of putrescine, spermidine and spermine by regulation of ODC 
induction via NF-кB as well as via c-myc 77. Since the polyamine metabolism plays a 
central role in hepatic regeneration 80, we conclude that ALR exerts its liver 
regeneration augmenting effect at least in part via activation of its signaling pathway 
leading to enhanced polyamine synthesis (Fig. 9). 
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Fig. 9: Signal transduction of ALR. ALR binds to its receptor (ALR-R) resulting in activation 
of mitogen-activated protein kinase MAPK cascade via phosphorylation of EGF-R 26. In 
addition, the activating protein-1 (AP-1) transcription factor family get activated after 
treatment with ALR in MAPK-dependent manner leading to cell growth and proliferation. 
Activated MAPK pathway leads also to elevated levels of polyamines via c-myc activation 
and ODC regulation 77. Intracellular ALR interacts with c-Jun activation domain-binding 
protein (JAB1) triggering AP-1 transcriptional activity 65. Dashed lines indicate that 
interaction/downstream effect might include several steps. 
We also have demonstrated that ALR protein expression were elevated in livers from 
patients with cirrhosis, hepatocellular and cholangiocellular carcinoma 81. 
Interestingly, the expression of ALR was inversely correlated with histological grading 
and angioinvasion of HCC suggesting that ALR may affect the invasiveness of HCC 
(manuskript in preparation). 
Recently, researchers aimed to investigate the potential therapeutic application of 
ALR expression in a model of rat hepatic fibrosis. Liver fibrosis is the process of 
accumulative deposition of collagen and other extracellular matrix (ECM) 
components resulting from enhanced ECM synthesis and decreased ECM 
degradation 82. In two studies an ALR recombinant plasmid was constructed and 
after application to rats with hepatic fibrosis reduced expression of TIMP-1 (tissue 
inhibitor of metalloproteinase), collagen type 1 and 3 was observed. Furthermore, a 
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marked reduction of ECM deposition in fibrotic liver tissue could be detected 83,84. 
Taken together, ALR has beneficial effects on rat hepatic fibrosis by i) ameliorating 
the regeneration capacity of injured liver cells and ii) reversing liver fibrosis through 
reduction of ECM deposition. 
3.5. ALR promoter and its regulation 
ALR has been shown to be involved in constitutive cellular processes such as protein 
folding 85 and mitochondrial maintenance 39,43, which are indispensable in all cell 
types. On the other hand, there might be inducible functions of ALR 26,27 under patho-
physiological circumstances such as acute liver diseases, liver cirrhosis and 
hepatocellular carcinoma 67,81. Therefore, it would be of interest to investigate the 
regulation of ALR expression under physiological as well as patho-physiological 
conditions. However, up to now, there is little known about the regulation of ALR and 
the transcriptional control of ALR expression. 
It was reported that the promoter region of ALR is TATA-less and has some 
characteristics of a housekeeping gene, oncogene, growth factor and transcription 
factors 86. They hypothesized that a functional initiator (Inr)-like element and its 
flanking repeat elements together comprise a core promoter controling the 
transcriptional initiation of ALR gene. This core promoter, located between -54 bp 
and +42 bp, could maintain constitutive expression of at least one transcript of 
ALR 86. On the other hand, it was shown that the major regulatory elements of the 
promoter of human ALR gene might exist in the region between -447 and -49 bp, and 
that a putative AP1/AP4 binding site (-375/-369 bp) may be crucial for basal and cell-
specific promoter activity. Interestingly, they found that this region was responsible 
for the AP1 binding which exhibited a negative transcriptional activity in HepG2 cells, 
while the transcription factor AP4 was involved in the positive regulation in Cos7 
cells. This dual regulation of AP1/AP4 cis-acting elements may account for 
differential expression of ALR gene in different tissues 87. 
A recent study revealed a transcriptional regulation of the -252/-49 bp region from the 
transcriptional start site of the human ALR gene in hepatocytes 88. They have 
demonstrated that SP1 functions as an essential transcriptional activator of basal 
expression of human ALR binding to the SP1 site (-152/-145) 88. SP1 was found to 
be constitutively expressed in almost all tissues expressing human ALR 24. In 
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addition, they have identified HNF-4α as another ALR regulating transcription factor 
and showed that HNF-4α could bind to its binding site (-209/-204), repress the hALR 
transcription and supress hALR gene expression in HepG2 cells 88. 
4. Liver-Enriched Transcription Factors/LETF 
Liver regeneration is a process which requires a wide variety of factors to achieve a 
successful tissue restoration. These factors include cytokines, growth factors, and 
transcription factors. In the liver, Liver-Enriched Transcription Factors (LETFs) play a 
central role in the regenerative process by maintaining the hepatocyte differentiation 
as well as controling the liver-specific gene expression 89. They bind different 
hepatocyte-specific DNA regulatory regions encoding essential proteins for liver 
functions such as plasma proteins, clotting factors and enzymes involved in hepatic 
metabolism 90-92. LETFs are classified by their ability to recognize specific DNA 
binding motifs and are divided into five major families: HNF1, HNF3, HNF4, HNF6, 
C/EBP and their corresponding isoforms 92-94. 
The HNF3 family, also termed Forkhead box (Fox) familiy 95, composes of three 
winged helix proteins: HNF3α, HNF3β and HNF3γ, also known as FOXA1, FOXA2 
and FOXA3, respectively. These proteins bind to DNA as monomer 96 and share 
strong homology (greater than 90%) in their DNA binding domain and therefore 
recognize the same DNA sequence 97. HNF3β plays an essential role in gene 
regulation in hepatocytes and in gastric, pancreatic, intestinal and bronchiolar 
epithelium 92. Based on cDNA microarrays technology, a wide variety of genes were 
found to be regulated during hepatic regeneration in livers from mice, who underwent 
partial hepatectomy. Interestingly, one of these genes is HNF3β (FOXA2), which was 
significantly upregulated (4,26 FC) two hours after hepatectomy, and declined after 
6 hours 98. 
Analysis of FOXA2 expression revealed not only a differential expression in HCC 
samples compared to normal liver tissue, but also demonstrated a constant 
upregulation of ALR in liver samples of patients with HCC 99. Similar to ALR 
expression, FOXA2 was also found to be regulated during liver regeneration as well 
as in hepatocellular carcinoma. Furthermore, overexpression of FOXA2 in 
hepatocytes led to elevated levels of ALR in FOXA2-transgenic mice 100. Taken 
together, 
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i) expression profiles of both ALR and FOXA2 are similar during liver regeneration 
as well as in liver samples of patients with HCC. 
ii) expression of ALR is enhanced in the FOXA2-overexpressing liver tissue. 
iii) promoter sequence of ALR exhibits putative binding sites for FOXA2. 
These findings hint at a potential role of FOXA2 in regulating ALR expression. 
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Aims of the study 
Liver regeneration is triggered and regulated by a variety of different factors, among 
them, ALR seems to play a major role due to its hepatotrophic and pro-proliferative 
effects. An organ-directed support/mediation of the regenerative process is of major 
clinical interest and might be a potential therapeutic application in the future. 
The goal of this thesis was to increase the understanding of how ALR expression is 
regulated and what impact an altered expression of ALR might have on the liver. 
In particular we aimed to investigate the expression profile of ALR during liver 
regeneration, the potential regulatory effect of regeneration-induced factors on the 
expression of ALR and the effect of intracellularly over-expressed ALR on hepatoma 
cells. The goals of this study are summarized as follows: 
• Investigation of ALR expression in distinct models of hepatic injury, as well as 
in hepatoma cells and primary human hepatocytes. 
• Analysis of the impact of liver associated factors, known to play a central role 
in liver regeneration, on the expression of ALR. 
• Analysis of ALR promoter and putative transcription factor binding sites. 
• Investigation of a putative regulation of ALR by the transcription factor FOXA2. 
• Analysis of ALR overexpression in hepatoma cells and its impact on cellular 
growth and transformation. 
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1. Materials 
1.1. Reagents, Chemicals, Kits, Solutions 
Reagents and chemicals 
Agarose Biozym, Hameln, Ger. 
Albumin Standard Pierce, Rockford, USA 
Ammonium persulfate (APS) Sigma, Steinheim, Ger. 
Ampicillin Roche, Mannheim, Ger. 
AMV-Reverse Transcriptase Promega, Madison, USA 
APAAP Sigma, Missouri, USA 
Aquatex Merck, Darmstadt, Ger. 
Bacto-Agar Difco-Laboratories, Detroit, USA 
Bacto-Trypton  Difco-Laboratories, Detroit, USA 
β-mercaptoethanol Roth, Karlsruhe, Ger. 
Bis-Acrylamide BIO-RAD, München, Ger. 
Bromphenol blue Serva, Heidelberg, Ger. 
BSA (Lipid-free) Sigma, Steinheim, Ger. 
Complete Mini Protease Inhibitor Cocktail Roche, Mannheim, Ger. 
DL-Norleucin Sigma, Steinheim, Ger. 
DMEM BioWhittaker, Verviers, Belgium 
EDTA (Di-sodium) Pharmacia Biotech, Freiburg, Ger. 
ECL Super Signal® West Pico Pierce, Rockford, USA 
ECL Super Signal® West Femto Pierce, Rockford, USA 
Epidermal growth factor (EGF) R&D Systems, Wiesbaden, Ger. 
Ethanol Merck, Darmstadt, Ger. 
Ethidium bromide Serva, Heidelberg, Ger. 
Fast Red Chromogen Roche, Penzberg, Ger. 
FCS Biochrom, Berlin, Ger. 
G-418 GIBCO BRL, Karlsruhe, Ger. 
GelPilot Mid Range Ladder Qiagen, Hilden, Ger. 
GlucaGen® Novo Nordisk Pharma, Mainz, Ger. 
Haematoxylin (Vektor H3404) Buringame, Canada 
Halt™ Protease Inhibitor Cocktail Kit Pierce, Rockford, USA 
HGF R&D Systems, Wiesbaden, Ger. 
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Hydrocortison100 Rotexmedica, Trittau, Ger. 
H2O Nuclease-free Promega, Madison, USA 
IFN-γ Tebu-Bio, Offenbach, Ger. 
IL-1 R&D Systems, Wiesbaden, Ger. 
IL-6 PeproTech GmbH, Hamburg, Ger. 
Insulin Lilly, Bad Homburg, Ger. 
Kanamycin Roche, Ingelheim, Ger. 
KGF R&D Systems, Wiesbaden, Ger. 
L-glutamine  Biochrom, Berlin, Ger. 
LPS Sigma, Steinheim, Ger. 
Mark12™ Protein Standard Invitrogen, Karlsruhe, Ger. 
MEM (Non-essential amino acid) Invitrogen, Scotland 
Methanol Merck, Darmstadt, Ger. 
Natrium chloride Merck, Darmstadt, Ger. 
Nucleic acid sample loading buffer (5x) BIO-RAD, München, Ger. 
O’GeneRuler™, DNA Ladder Mix Fermentas, St. Leon-Rot, Ger. 
PDGF R&D Systems, Wiesbaden, Ger. 
Penicillin/Streptomycin Biochrom, Berlin, Ger. 
Ponceau S Sigma, Steinheim, Ger. 
Powdered Milk Carl Roth, Karlsruhe, Ger. 
Potassium chloride Merck, Darmstadt, Ger. 
Potassium dihydrogenphosphate Merck, Darmstadt, Ger. 
Phosphate Buffered Saline w/o Ca2+/Mg2+ PAA, Pasching, Austria 
Proteinase K Qiagen, Hilden, Ger. 
Ready-Load™ 1kb DNA Ladder GIBCO BRL, Karlsruhe, Ger. 
Restrictionendonucleases NEB, Frankfurt, Ger. 
SDS Sigma, Steinheim, Ger. 
siPort™ XP-1 Ambion, Austin, USA  
T4-DNA-Ligase GIBCO BRL, Berlin, Ger. 
Taq-DNA-Polymerase Roche, Mannheim, Ger. 
TEMED Merck, Darmstadt, Ger. 
TNF-α PeproTech GmbH, Hamburg, Ger. 
TRIS Ultrapure USB, Cleveland, USA. 
Triton X-100  Boehringer, Mannheim, Ger. 
Trypan blue solution (0.4%)  Sigma, Steinheim, Ger. 
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Trypsin/EDTA Sigma, Deisenhofen, Ger. 
Tween®20 Merck, Darmstadt, Ger. 
1,4-Dithiothreit (DTT) Roth, Karlsruhe, Ger. 
100 bp Ladder, DNA Pharmacia, Freiburg, Ger. 
3% human serum (block solution) BIO-RAD, München, Ger. 
Kit systems 
BCA Protein Assay Kit Pierce, Rockford, IL, USA 
CellTiter 96® AQueous Proliferation Assay Promega, Madison, USA 
DNeasy Tissue Kit Qiagen, Hilden, Ger. 
Dual-Luciferase® Reporter Assay System Promega, Madison, USA 
ECL™ Western Blotting Analysis System Amersham, Braunschweig, Ger. 
FastStart DNA Master SYBR Green I Roche, Basel, Switzerland 
HaltTM Protease Inhibitor Cocktail Kit Pierce, Rockford, USA 
LightShift® Chemiluminescent EMSA Kit Pierce, Rockford, USA 
MycoAlert® Mycoplasma Detection Kit Cambrex, Rockland, USA 
NE-PERTM Extraction Reagents Pierce, Rockford, USA 
Plasmid Maxi Kit Qiagen, Hilden, Ger. 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Ger. 
QIAquick Gel Extraction Kit Qiagen, Hilden, Ger. 
QIAquick PCR Purification Kit Qiagen, Hilden, Ger. 
Reverse Transcription System Promega, Madison, USA 
RNeasy Mini Kit Qiagen, Hilden, Ger. 
Migration assay BD Bioscience, Heidelberg, Ger. 
Invasion assay BD Bioscience, Heidelberg, Ger. 
Antibodies 
Antibody Host Provider 
Polyclonal anti-human ALR Rabbit Davids Biotech., Rgbg, Ger. 
Polyclonal anti-human FOXA2 Goat Santa Cruz, CA, USA 
Polyclonal anti-human β-actin Rabbit Santa Cruz, CA, USA 
Polyclonal Anti-rabbit  Mouse Dako, Hamburg, Ger. 
III. Materials & Methods 
 
30 
Polyclonal Ig-mouse Rabbit Dako, Hamburg, Ger. 
Polyclonal IgG Rabbit Sigma, München, Ger. 
Polyclonal anti-rabbit  Goat DAKO, Hamburg, Ger. 
APAAP complex mouse DAKO, Hamburg, Ger. 
Polyclonal anti-human CDH1 Rabbit Cell Signaling, Danvers, USA 
Polyclonal anti-human HIF-1α Rabbit Novus Biologicals, CO, USA 
Poylclonal anti-human SNAIL Rabbit Santa Cruz, CA, USA 
Films and membranes 
Biodyne® Nylon Transfer Membranes PALL, Dreieich, Ger. 
Chromatography paper, 3 mm Whatman, Dassel, Ger. 
ECL Hyperfilm Amersham, Freiburg, Ger. 
PVDF-Membrane, 0,45 µm PALL, Dreieich, Ger. 
 
Organisms and plasmids 
Organisms Characteristics Reference/Number 
Caco-2 Human colorectal cancer cells ATCC/HTB-37 
E. coli GC 10 Competent cells for cloning Biomol, Hamburg, Ger. 
HepG2 Human hepatoma cells ATCC/HB-8065 
HepG2.2.15 Human hepatoma cells ATCC/CRL-11997 
Hep3B Human hepatoma cells ATCC/HB-8064 
Huh-7D12 Human hepatocellular cells ECACC/01042712 
H1299 Human cell lung cancer cells ATCC/CRL-5803 
PHH Primary human hepatocytes this work 
PLC Human hepatoma cells ATCC/CRL-8024 
 
 
Plasmids Marker Reference 
pcDNA3.1 (see appendix) Ampr Invitrogen, Karlsruhe, Ger. 
Constructs based on pcDNA3.1 Ampr this work 
pGL2-Basic (see appendix) Ampr Promega, Madison, USA 
Constructs based on pGL2-Basic Ampr this work 
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Preparation of solutions 
 
Ad to 1L Aqua dest. 
10 ml Tween®20
500 ml 20x PBS 
PBS, 10× + 1% Tween  
 
 
 
 
 
 
 
 
 
Anode Buf
 
Methanol 
 
 
Tris Cl (1 M) 
 
A
 
 
 
 
 
 
 
 
 
 
 
 
 
For reducing conditions add 100 mM DTT or 25 µl/ml β-mercaptoethanol 
 
 
 
 
 
 
Ad to 500 ml qua dest. 
12,5 ml (25 mM) 
100 ml (20%) 
fer A  
Ad to 500 ml Aqua dest. 
150 ml (0,3 M) Tris Cl (1 M) 
100 ml (20%) Methanol 
Anode Buffer B  
Ad to 1L Aqua dest. 
100 ml 10x PBS 
PBS, 1× + 0,1% Tween  8 g (29,4 mM) KH2PO4
56,8 g (159,5 mM) 2HPO4 x 2H2O 
8 g (53,7 mM) 
320 g (2,74 M) 
PBS, 20× 
12,5 ml (25 mM) 
2,63 g (40 mM) in 
  
6 ml (10 %) 
10 mg (0,1 %)
2 ml (2 %)  
6 ml (300 mM)  
20 ml (0,5 M) 
27,5g (0,445 M) 
× TBE-buffer (DNA) 
NaCl 
KCl 
Na
Aqua dest. Ad to 2L 
Cathode Buffer
DL-Norleuc
Tris Cl (1 M) 
Aqua dest. Ad to 500 ml 
6
Ad to 1L Aqua dest. 
10 g (1 %) SDS 
144 g (1,9 M) Glycin 
30,2 g (250 mM) Tris Base 
10× SDS –Gel running Buffer × SDS loading Buffer (Laemmli dye)
Ad to 10 ml 
Tris Cl (0,5 M, pH 6,8)
SDS (10 %) 
Bromphenolblau 
Glycerin 
Aqua dest. 
5
Tris 54 g (0,445 M) 
Boric acid 
EDTA (pH 8,0) 
Aqua dest. Ad to 1L 
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Ethidium bromide stock solution (DNA) 
10 mg/ml ethidium bromide in H2O 
1.2. Oligonucleotides 
All sequences are denoted from 5’ to 3’. 
For Cloning 
Oligonucleotides were ordered from Sigma/Genosys (Steinheim, Germany). 
 
Primer Sequence 
hALR-Pro-Bgl2-Fwd ata gat ctc gca agg agg cac agg aat ccc 
hALR-Pro-HindIII-Exon1-Rev ata agc ttc cac gtc ttg aag tcg acg cag g 
hALR-Pro-HindIII-Exon2-Rev ata agc ttg cgg aag cag gcc gac cga gag 
For Sequencing 
Sequencing analysis were performed by GENEART (Regensburg, Germany) using 
free of charge oligonucleotides (T7-promoter and BGH reverse primer). 
For Gene expression 
The mRNA sequences for ALR, FOXA2 and 18S ribosomal RNA were derived from 
GenBank and the primers were designed using OligoPerfect™ Designer tool 
(Invitrogen, Karlsruhe, Germany). If not otherwise noted, the oligonucleotides were 
obtained from Sigma/Genosys (Steinheim, Germany). 
 
Primer Sequence 
hALR-Fwd. cac aat gaa gtg aac cgc aag 
hALR-Rev. cac cca act gag aca caa cag 
mALR-Fwd. cac agg atc ggg aag aat tg 
mALR-Rev. att cct cgc agg ggt aaa ac 
rALR-Fwd. agc ggg aca tca agt tta gg 
rALR-Rev. atg aac tgg gcc ata tcc tg 
hMMP-1-Fwd. tca cca agg tct ctg agg gtc aag c 
hMMP-1-Rev. gga tgc cat caa tgt cat cct gag c 
hMMP-3-Fwd. obtained from Tib molbiol (Berlin, Germany) 
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hMMP-3-Rev. obtained from Tib molbiol (Berlin, Germany) 
18S Ribosomal RNA-Fwd. gta acc cgt tga acc cca tt 
18S Ribosomal RNA-Rev. cca tcc aat cgg tag tag cg 
For EMSA 
Oligonucleotides were ordered from Metabion (Martinsried, Germany) 
 
Oligonucleotide Sequence 
wt FOXA2-Fwd. tgc ccg att tct ccc agc ccc gcg c 
wt FOXA2-Rev. gcg cgg ggc tgg gcg aaa tcg ggc a 
wt FOXA2-Biotin-Fwd. Biotin-tgc ccg att tct ccc agc ccc gcg c 
wt FOXA2-Biotin-Rev. Biotin-gcg cgg ggc tgg gcg aaa tcg ggc a 
wt IL6-RE–Fwd. acc ccg gca gag ctt ccc agg gtt g 
wt IL6-RE-Rev. caa ccc tgg gaa gct ctg ccg ggg t 
wt IL6-RE–Biotin-Fwd. Biotin-acc ccg gca gag ctt ccc agg gtt g 
wt IL6-RE–Biotin-Rev. Biotin-caa ccc tgg gaa gct ctg ccg ggg t 
wt C/EBPβ-Fwd. cca ggg ttg cct gtc cct gaa cct t 
wt C/EBPβ-Rev. aag gtt cag gga cag gca acc ctg g 
wt C/EBPβ-Biotin-Fwd. Biotin-cca ggg ttg cct gtc cct gaa cct t 
wt C/EBPβ-Biotin-Rev. Biotin-aag gtt cag gga cag gca acc ctg g 
1.3. Technical equipment 
Balance ScalteC-SBA53 Denver Instrument, Göttingen, Ger. 
Biofuge 15R Heraeus, Hanau, Ger. 
BioPhotometer 6131 Eppendorf, Hamburg, Ger. 
Blue Blot Wet/100 Serva Electrophosesis,Heidelberg, Ger. 
Cell culture Incubator BB6220 Heraeus, Hanau, Ger. 
Centrifuge 5417C Eppendorf, Hamburg, Ger. 
Centrifuge 5417R Eppendorf, Hamburg, Ger. 
Digital camera colorview 12 Olympus, Hamburg, Ger. 
ELISA-reader GENios plus Tecan, Stuttgart, Ger. 
Freezing container Nalgene, Rochester, USA 
Horizontal Shaker KS250 basic IKA® Labortechnik, Staufen, Ger. 
Hypercassette Neutral Amersham, Buckinghamshire, UK 
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Kodak Film Processor M35 X-Omat Kodak, Stuttgart, Ger. 
LaminAir® Hood HB2474 Heraeus, Hanau, Ger. 
LightCycler® 1.2 Instrument Roche, Basel, Switzerland 
LUMAT LB9501 Berthold, München, Ger. 
Magnetrührer RCT basic B IKA® Labortechnik, Staufen, Ger. 
Megafuge 1.0R Heraeus, Hanau, Ger. 
Microscope Leica DMIL Leica microsystems, Wetzlar, Ger. 
Microwave Inverter NN-SD456W Panasonic, Hamburg, Ger. 
Mini centrifuge 5415D Eppendorf, Hamburg, Ger. 
Milli-Q Biocel Millipore, Bradford, USA 
Mini Transblot Cell Bio-Rad Laboratories, München, Ger. 
Peltier Thermal Cycler PTC-200 Biozym, Oldendorf, Ger. 
PH-Meter 766 calimatic Knick, Berlin, Ger. 
Powerpack 200 Bio-Rad, München, Ger. 
Semi Dry Transfer Cell Trans-Blot SD Bio-Rad, München, Ger. 
Shaker Certomat R Vitaris, Baar, Switzerland 
Shaking water Bath 1092 GFL, Burgwedel, Ger. 
SONOPULS HD 2070 Bandelin, Berlin, Ger. 
Sub-Cell® GT Bio-Rad Laboratories, München, Ger. 
Thermomixer Eppendorf, Hamburg, Ger. 
Varioklav® Thermo Electron, Oberschleißheim, Ger. 
Vortex mixer Genie 2 Scientific Industries, NY, USA 
Wide Mini-Sub® Cell GT Bio-Rad Laboratories, München, Ger. 
1.4. Databases research 
BLAST http://www.ncbi.nlm.nih.gov/BLAST 
PubMed http://www.ncbi.nlm.nih.gov/entrez 
TESS http://www.cbil.upenn.edu/cgi-bin/tess 
TFsearch http://www.cbrc.jp/research/db/TFSEARCH.html 
Transfac http://www.gene-regulation.com/pub/databases.html 
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2. Methods 
2.1. Primary cells and cell lines 
2.1.1. Isolation of primary human hepatocytes 
Tissue samples from human liver resections were obtained from patients undergoing 
partial hepatectomy for metastatic liver tumors of colorectal cancer. Experimental 
procedures were performed according to the guidelines of the charitable state 
controlled foundation HTCR (Human Tissue and Cell Research), with the informed 
patient’s consent 101 approved by the local Ethical Committee of the University of 
Regensburg. Human hepatocytes were isolated using a modified two-step 
EGTA/collagenase perfusion procedure and maintained in culture as described 
previously 76,102. Viability of isolated hepatocytes was determined by trypan blue 
exclusion method and cells with a viability > 85% were used for cell culture 
experiments. 
2.1.2. Cultivation of hepatocytes and cell lines 
Hepatocytes were plated in collagen-coated 6-well plates (BD BioCoat™ Collagen I) at 
a density of 1,0 x 105 cells/cm2 in appropriate volume of culture media. The medium 
consisted of Dulbecco's modified Eagle's medium with 5% fetal calf serum, 2 mM 
L-glutamine, and supplements as follows: 1,7 mU/ml insulin, 3,75 ng/ml 
hydrocortisone, 100 µg/ml streptomycin, 100 U/ml penicillin. 24 h after plating, medium 
was replaced by medium with 0,5% FCS. Cells were incubated at 37°C in a humidified 
incubator with 5% CO2. Viability of hepatocytes during culture period was monitored by 
cell morphology (light microscopy, image analysis) and determination of enzyme 
release into culture medium (aspartate aminotransferase activity). 
Cell lines were cultured in DMEM supplemented with 10% inactivated FCS, 
L-glutamine (2 mM), antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) and 
0,1 mM non-essential amino acids (MEM). FCS was incubated at 56°C for 30 min in 
order to inactivate the complements. Cells were grown in monolayer T-75 flasks with 
approximately 10 ml of medium until confluency. 
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Cell passaging 
Cell cultures were split at a ratio of 1:3 to 1:5 in fresh medium every 3-4 days. 
Adherent cells were washed once with PBS and either scrapped or disaggregated by 
incubation with 0,05% Trypsin/0,02% EDTA/PBS (2-3 ml per 75 cm2 culture vessel 
area) at 37°C for 5 min until cells detached. Trypsin was then inactivated by adding 
6 ml medium with 10% FCS. After centrifugation at 30 g for 7 min, the supernatant 
was discarded and the cells were resuspended and plated. 
Assessing cell vitality 
Number of viable cells was determined by trypan blue exclusion method. The cell 
suspension was diluted with 0,2% (w/v) trypan blue solution and the cells were 
counted in a Neubauer haemocytometer. 
Freezing and thawing cells 
Confluent cells were harvested, washed with PBS and pellet obtained at 30 g was 
frozen in DMSO/DMEM (1:10) including 10% FCS. To allow gradual freezing at a rate 
of 1°C/min, the cryo-vials were placed in isopropanol-filled cryo-containers and frozen 
at -20°C for 2 h and then transferred to -80°C for 48 h. For long-term storage, samples 
were stored in liquid nitrogen. 
In contrast, frozen cells were rapidly thawed by resuspending them in 5 ml warm 
medium. The cells were then centrifuged at 30 g for 7 min, the supernatant was 
discarded, and the cells were washed and plated with standard medium including 10% 
FCS. Next day, medium was replaced to remove all traces of DMSO. 
2.1.3. Stimulation and treatment of cells 
For stimulation experiments, 10,5 x 103 cells/cm2 were seeded into each well in 6-well 
plate with medium containing 10% FCS. 24 hours after plating, the medium was 
replaced by serum-free medium for the next 24 hours. Cells were then incubated in 
fresh serum-free medium in the absence or presence of different growth factors and 
cytokines for another 24 hours until they were harvested. Treatment was performed in 
triplicates at least 3 times. 
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Stimulating agents were used at following concentrations: 
 
Stimulator Final concentration 
HGF 10 ng/ml 
EGF 20 ng/ml 
KGF 100 ng/ml 
PDGF 10 ng/ml 
IFN-γ 5000 U/ml 
LPS 1 µg/ml 
Et-OH 0,1% 
Insulin 0,5 U/ml 
IL-1 250 U/ml 
IL-6 30 ng/ml 
TNF-α 10 ng/ml 
2.1.4. Transfection of cell lines 
Transient transfection of luciferase-reporter plasmids 
For transfections, HepG2 cells were cultured as mentioned above. The passage 
number of the cells ranged from P10- P20 from the ATCC stock culture. 
10,5 x 103- 21 x 103 cells/cm2 were seeded in 6-well plate over night. After 24 hours, 
0,5 µg of hALR promoter constructs (construct 1: -733 to +240 bp, and construct 2: 
-733 bp to + 502 bp) were transiently co-transfected with 0,1 or 0,5 µg of the 
expression plasmid pcDNA3.1-FoxA2 (gift from R. H. Costa) using the siPORT™ XP-1 
Transfection Agent following manufacturer’s instructions. To determine the 
transfection efficiency, pRL-TK Renilla-vector was co-transfected. The promoterless 
vector pGL2-Basic served as negativ control. 
Luciferase reporter assays 
24 hours after transfection, cells were washed twice with PBS then lysed in 500 µl 
Reporter lysis Buffer (Promega) using a shaker. In order to perform the DLRTM Assay, 
100 µl of LAR II were predispensed into a luminometer tube into which 20 µl of cell 
lysate were transferred. After mixing the firefly luciferase activity was measured using 
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the luminometer LB9507 (Berthold). Afterwards, 100 µl of Stop & Glo® Reagent were 
added into the tube, briefly mixed and the Renilla luciferase activity was immediately 
measured. Each experiment was repeated three times and all measurements were 
performed in triplicates. Results are expressed in comparison to promoterless 
pGL2-Basic vector activity. 
Stable transfection of HepG2 cells 
For transfection of expression plasmid pcDNA3.1-hALR into the HepG2 cells, 
siPORT™ XP-1 Transfection Agent, a polyamine-based DNA transfection reagent, was 
used following Ambion instructions. Briefly, one day prior to transfection 
21 x 103 HepG2 cells/cm2 were seeded per well into a 6-well plate in normal growth 
medium, until 30-60% confluency after 24 hours. Next day, 2 µl transfection reagent 
was added to 98 µl medium, shortly vortexed and incubated at RT for 20 min. 
Afterwards, 0,5 µg DNA was added, mixed gently by flicking, and further incubated for 
20 min at RT to allow the formation of the transfection-complex. In the meantime, cells 
were washed and incubated with 1,9 ml normal growth medium. Finally, 100 µl of the 
transfection-complex were applied dropwise onto the cells. The empty vector 
pcDNA3.1 was transfected into HepG2 cells and served as mock-control. 
Antibiotic selection of stable-transfected HepG2 cells 
48 hours after transfection, cells were cultured based on positive selection with G-418. 
A concentration of 1 mg/ml G-418 was used for the selection process. The normal 
growth medium supplemented with G-418 was renewed every 2 days. The selection 
time varied from 12 to 14 days and ended after all cells of the non-transfected control 
were dead. The picking of clones was started when round clones with a shiny, well-
defined border appeared. The concentration of G-418 during cultivation was 
0,4 mg/ml. 
Picking, expansion and freezing of HepG2 clones 
Each individual drug-resistant clone was picked from the selection plate using a 
pipette with a yellow tip adjusted to a volume of 20 µl. 24 clones were picked, 
transferred into a 48-well plate and further cultured under normal conditions. Once 
clones reached confluency, they were split into 24-well plate. The cells were then 
expanded in T-75 culture flasks and when they reached 80% confluency, they were 
frozen and stored in liquid nitrogen. 
III. Materials & Methods 
 
39
2.1.5. Migration and invasion assay 
To determine the effect of over-expressed ALR on cell motility, migration assays were 
performed using modified Boyden chambers. Briefly, 0,5 x 105 of both wt- and stably 
ALR expressing HepG2 cells were resuspended in 1% FCS-DMEM and seeded into 
inserts with 8 μm filter pores, which were either uncoated (migration assay) or 
matrigel-coated (invasion assay). 10% FCS-DMEM served as a chemo-attractant. 
After 48 hours, cells were fixed and stained with Diff-Quick and all migrated or invaded 
cells were counted. 
2.2. Protein biochemical methods 
2.2.1. Preparation of cell protein extracts from mammalian cells 
Isolation of whole cellular proteins 
The cells were washed twice with cold PBS to remove residual proteins of the FCS 
which cause high background signals by unspecific antibody binding. Cells were 
harvested by scrapping in cold RIPA-Buffer containing protease inhibitors. Afterwards, 
the samples were homogenized by sonification and the homogenate was centrifuged 
at 20,000 g for 20 min at 4°C. The supernatant was transferred into 1,5 ml Eppendorf 
cups and the proteins were used immediately for protein determination or stored at 
-20°C. 
Isolation of nuclear proteins 
In order to isolate the nuclear proteins, NE-PERTM Nuclear and cytoplasmic Extraction 
Reagents was used following PIERCE instructions. 2 x 106 HepG2 cells were washed 
with cold PBS and centrifuged at 500 g for 3 min. The supernatant was carefully 
removed, and the pellet was resuspended with 200 µl of ice-cold CER I. After 
vortexing for 5 sec and incubating on ice for 1 min, the sample was centrifuged at 
16,000 g for 5 min, and the supernatant containing the cytoplasmic extract was 
transferred to a clean pre-chilled tube. The insoluble pellet-fraction was then 
resuspended with 100 µl of ice-cold NER and vortexed at maximum speed for 15 sec. 
Afterwards, the sample was incubated on ice and vortexed for 15 sec every 10 min, for 
a total of 40 min. Subsequently, the sample was centrifuged at full speed 16,000 g for 
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10 min, and the supernatant containing the nuclear fraction was transferred to a clean 
pre-chilled tube. All extracts were then used to determine the protein concentration 
and immediately stored at -80°C until use in many downstream assays. 
Determination of protein concentration 
For protein quantification, the BCA Assay protein Quantitation Kit was used. The 
method is based on the reduction of Cu2+-ions to Cu1+-ions in alkaline environment 
(Biuret reaction). The Cu1+-ions form a complex with bicinchonic acid (BCA) a purpled 
colored complex with a peak absorption at 562 nm. The absorption is linear in a range 
of 20-2000 µg/ml and is proportional to the protein concentration. BCA reagent was 
freshly prepared by adding 4% CuSO4 to the protein solution at a ratio of 1:50. 10 µl of 
the probe or the standard were added to a microtiter 96-well plate and mixed with 
200 µl of the prepared BCA solution. After incubation at 37°C for 30 min the extinction 
was measured in the TECAN’s microplate reader GENios Plus and the protein 
concentration was calculated. 
2.2.2. SDS-Polyacrylamid-Gel Electrophorese (SDS-PAGE) 
Protein samples were separated according to their size by using a discontinuous gel 
system, which is composed of stacking (5%) and separating gel (14%) layers which 
differ in salt and acrylamide concentration. 
For gel electrophoresis, the stacking and separating gels were prepared as follows: 
 
 Stacking gel Separating gel 
40% acrylamid 312,5 µl 1750 µl 
0,5 M Tris.Cl (pH 6,8)/1 M Tris.Cl (pH 8,8) 312,5 µl/- -/1250 µl 
10% SDS 25 µl 50 µl 
H2O 1825 µl 1900 µl 
Tetramethylethylenediamine (TEMED) 2,5 µl 2 µl 
10% Ammonium persulfate (APS) 25 µl 50 µl 
 
Next day, the separating gel was cast and overlaid with water-saturated isobutanol 
until polymerization is finished. After 1 hour isobutanol was discarded and the stacking 
III. Materials & Methods 
 
41
gel was poured on top of the separating gel, and the comb inserted immediately. After 
polymerization, the stacking gel was mounted in the electro-phoresis tank, which was 
filled with running buffer. 20 µg of protein lysate were denatured by adding 3 x SDS 
sample buffer ± 100 mM DTT incubating at 95°C for 10 min. The gel was run with 
125 volt until the sample reached the surface of the stacking gel, then the current was 
increased to 160 volt and the gel was run for 2-4 h. 
2.2.3. Western Blot analysis 
After separation by SDS-PAGE, proteins were transferred electrophoretically onto a 
Polyvinylidene Fluoride (PVDF) microporous membrane using a Trans-Blot SD 
Semi-Dry Transfer Cell (Bio-Rad). The transfer conditions were 43 mA for 45 min at 
RT. Next steps were then performed as follows: 
 
 
 B
 
Pr
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Signal detection was performed using SuperSignal West Pico Chemiluminescent 
Substrate according to Thermo-Scientific’s instruction and the blots were exposed to 
an autoradiography film (Hyperfilm ECLTM, Amersham) for 5 sec to 30 min depending 
on the signal intensity. 
Stripping of membranes 
This method was perfomed as described in Restore™ Western Blot Stripping Buffer 
booklet. Briefly, the membrane was incubated with stripping buffer for 15 min at RT, 
then washed twice using large volumes of wash buffer at RT. Afterwards, 
immunodetection of other proteins was performed. 
5 x 5 minutesPBST (0,1%)ashing
1 hour1:10000/5% non-fat dry milk econd antibody
5 x 5 minutesPBST (0,1%)shing
Over nightVariable/5% non-fat dry milk imary antibody
2 hours5% non-fat dry milk/PBST (0,1%)locking
DurationDiluation/Solution
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2.2.4. Immunohistochemistry (IHC) 
Immunostaining was performed using Alkaline Phosphatase-Anti-Alkaline 
Phosphatase (APAAP) complex method. 
Preparation, fixation and permeabilization of slides 
2 µm sections were cut from paraffin-embedded tissue and transferred to silanized 
glass slides (Super Frost™). The slides were deparaffinized in xylene for 20 min at RT 
and rehydrated in graded concentrations of ethyl alcohol (100%, 96%, 90%, 80%, 
70%) then water. To enhance the antigen retrieval, sections were treated with 
Proteinase K diluted in 50 mM Tris-Puffer (PH 7,5) (1:4) at RT for 10 min and then 
washed in distilled water. 
Blocking and staining 
The sections were placed into PBS buffer containing 3% human serum (block solution) 
for 30 min. Primary polyclonal anti-ALR antibody diluted 1:600 (0,16 mg/ml) in block 
solution was pipetted onto the slides and incubated overnight at 4°C. The slides were 
washed three times with PBS buffer and incubated with 1:50 diluted secondary mouse 
anti-rabbit antibody for 1 h. Slides were then washed with PBS and incubated for one 
additional hour with Ig-mouse-antibody. After washing with PBS, slides were incubated 
with the mouse APAAP complex at RT for 30 min. Staining was completed with a 20 
min incubation using Fast Red Chromogen in 0,1 M TRIS buffer pH 8,2. Counter-
staining was performed with haematoxylin and rabbit IgG was used as isotype control. 
2.3. Nucleic acid methods 
2.3.1. RNA-related methods 
2.3.1.1. RNA isolation, reverse transcription and cDNA synthesis 
The cells were washed twice with PBS, and harvested using RLT Buffer containing 
β-mercaptoethanol and proteinase K. The cells were collected in clean RNase-free 
1,5 ml Eppendorf tubes and were either stored at -80°C or used immediately for RNA 
extraction. Total RNA was isolated using the RNeasy Mini Kit according to Qiagen’s 
instructions. The cell lysate was sucked at least 5 times through a blunt 20-gauge 
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needle (0,9 mm diameter) fitted to a RNase-free syringe. After homogenization, the 
cell lysate was mixed with 1 volume of 70% ethanol, applied onto RNeasy Mini Spin 
Columns and centrifuged at 8,000 g for 15 sec, the columns were washed by adding 
RW1 buffer and centrifuged at 8,000 g for 15 sec, then re-washed twice with RPE 
buffer. Afterwards, the silica-gel membranes were dried by centrifugation the columns 
at maximum speed for 1 min followed by elution of total RNA with 20-30 µl RNase-free 
water centrifuging for 1 min at maximum speed. The concentration of eluted total RNA 
was determined by a UV spectrophotometer. Purified total RNA was either stored at 
-80°C or was used immediately to prepare cDNA. AMV Reverse Transcription System 
from Promega was used to synthesize single-stranded cDNA from total RNA. 1 µg of 
total RNA was reverse transcribed in a 20 µl reaction mixture containing 4 µl MgCl2 
(25 mM), 2 µl Reverse Transcription Buffer (10x), 2 µl dNTP mixture (10 mM), 0,5 µl 
RNasin® Ribonuclease Inhibitor, 0,75 µl AMV Reverse Transcriptase and 1 µl Oligo 
(dT15) Primer, in a total volume of 20 µl. he 1 µg RNA is placed in a RNase-free cup 
and incubated at 70°C for 10 min, then the mix is added and the cup is incubated at 
42°C for 60 min. The sample was then heated at 95°C for 5 min to inactivate the AMV 
Reverse Transcriptase and to prevent it from binding to the cDNA and the reaction 
was immediately cooled on ice for at least 5 min. The synthesized cDNA was 
immediately used for PCR or stored at -20°C until usage. 
2.3.1.2. Polymerase chain reaction (PCR) 
Amplifying of hALR-cDNA 
In order to generate an expression plasmid of hALR, PCR was performed to amplify 
hALR-cDNA (378 bp) in 50 µl containing: 
 Volume (µl) 
cDNA 1 
Forward Primer (10 µM) 0,5 
Reverse Primer (10 µM) 0,5 
10x PCR Buffer 5 
dNTP (10 mM) 1 
MgCl2 (50 mM) 1,5 
Taq Polymerase (5 U/µl) 0,5 
H2O 31 
III. Materials & Methods 
 
44 
The PCR was started by heating the sample at 94°C for 5 min, followed by 35 cycles 
of following program: 
 
 Denaturation Annealing Extention 
Temperature 94°C 60°C 72°C 
Time 1 min 1 min 1,5 min 
After loading the PCR product on a 1,5% agarose gel, the specific amplicon was gel-
extracted and purified using QIAquick Gel Extraction Kit according to Qiagen’s 
Instruction. 
Amplifying of genomic DNA 
To generate the luciferase-reporter constructs, PCR was used to amplify specific 
regions of the hALR promoter sequence using Taq PCR Core Kit according to 
Qiagen’s instructions. Briefly, 70 ng/µl human genomic DNA was amplified in 25 µl 
reaction containing 1x PCR-Buffer, 1x Q-Solution, 10 mM dNTP, 1,5 mM MgCl2, 
10 µM of both forward and reverse primer and 0,025 Unit Taq DNA Polymerase. The 
template was denatured at 94°C for 5 min followed by 35 cycles of: 
 
 Denaturation Annealing Extention 
Temperature 94°C 64°C 72°C 
Time 1 min 1,5 min 1,5 min 
 
The elongation step was completed by incubation for 5 min at 72°C and the reaction 
was cooled to 4°C. Afterwards, the samples (Amplicon 1: 995 bp and Amplicon 2: 
1281 bp) were loaded on an agarose gel (1%) and following gel electrophoresis. The 
PCR products were verified by sequencing (GENEART). Due to the terminal 
transferase activity of the Taq polymerase, a single deoxyadenosine was added to the 
3´end of PCR products, making them usable for TA-cloning. The amplicons were then 
cloned into pBAD-TOPO-TA vector. 
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2.3.1.3. Real-Time Polymerase Chain Reaction (RT-PCR) 
Gene expression monitoring with SYBR-Green I dye 
The LightCycler experiments were performed with the hot-start DNA Master 
SYBRGreen I kit and using the LightCycler® apparatus (Roche, Germany) following 
the manufacturer’s instructions. The primers used in the PCR reaction were generated 
by Metabion. 
The amplification was carried out in a total volume of 20 µl containing 1 µl non-deluted 
cDNA, 2,4 µl MgCl2 (50 mM), 0,5 µl of each of the sense and antisense primers 
(10 µM) and 2 µl of Fast-Start Mix (containing buffer, dNTPs, SYBR-Green dye and 
Taq polymerase). A standard curve was generated for the housekeeping gene pair by 
amplifying three dilutions (1; 1:10; 1:100) of the most concentrated sample. The 
18S ribosomal-RNA housekeeping gene served as an internal control and was used to 
normalize for differences in the amount of cDNA. 
The amplification program consisted of 1 cycle of 95°C with a 10 min hold (hot start) 
followed by 50 cycles of 95°C with a 15 sec hold, 62°C annealing temperature with a 
5 sec hold and 72°C with a 10 sec hold. Amplification was followed by melting curve 
analysis to verify the correctness of the amplicon. A negative control without cDNA 
was run with every PCR to assess the specificity of the reaction. Analysis of data was 
performed using LightCycler software version 3.5. 
The slope of the standard curve was an indicator of the amplification efficiency. 
Standard curves were subsequently used to calculate the relative abundance of each 
transcript in each sample. The measurements were performed in triplicates. All results 
are represented as mean ± SD. 
2.3.2. DNA-related methods 
2.3.2.1. Molecular cloning 
Restriction endonuclease digestion 
To verify the presence and orientation of plasmid-inserts, or to clone insert DNA into a 
plasmid, DNA was digested with appropriate restriction enzymes. The restriction 
digest can either be performed analytically to analyze the DNA or preparative to 
prepare DNA for further cloning. Enzymes and their buffers were purchased from 
Roche or New England Biolabs (Germany). The digestion of plasmid DNA or PCR 
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products was carried out using 5 U enzyme/1 µg DNA in 20 µl at 37°C for 2 h. 
Afterwards, the reaction was stopped by incubating for 15 min at 65°C. 
Dephosphorylation of plasmid-DNA with alkaline phosphatase 
To prevent re-ligation of cohesive ends dephosphorylation was carried out. Digested 
vectors were treated with shrimp alcaline phosphatase (SAP) to remove the 
5´-phosphate at 37°C for 10 min followed by heat–inactivation of the SAP for 15 min at 
65°C. The sample can directly be used for ligation. 
Purification of plasmid-DNA by gel extraction 
After dephosphorylation, the DNA vector was purified by running on an ethidium 
bromide-containing agarose gel, excising the band containing the fragment under UV 
illumination and subsequent gel extraction using QIAquick Gel Extraction Kit following 
Qiagen’s instructions. 
Ligation 
In the presence of ATP and Mg2+ ions T4-DNA-ligase is able to covalently join blunt or 
cohesive ends by a phosphodiester bridge between a 5´-phosphate and a 3´-OH 
group. After gel extraction, the dephosphorylated vector was used as follows: 
 
Insert-DNA 3 µg 
T4 DNA ligase 1 µl 
5x T4 DNA ligase-buffer 4 µl 
H2O variable 
Total 20 µl 
 
The mixture was incubated at 25°C for 1,5 h then at 37°C for 30 min followed by 
overnight incubation at 13°C and subsequently used for transformation of E. coli. 
Transformation of competent E. coli 
50 µl of GC5-competent cells were thawed on ice, mixed by pipetting with 5 µl ligation 
mixture and immediately placed on ice for 30 min. Then, the mixture was heat-
shocked for 30 sec in a 42°C water bath followed by incubation on ice for 2 min. 
Afterwards, 250 µl LB-medium were added to the reaction and the mixture was then 
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incubated at 37°C for 1 h with shaking at 300 rpm. In case of ampicillin selection, cells 
were then directly plated on pre-warmed LB-selection plates (37°C) and placed 
overnight in an incubator at 37°C. 
Plasmid isolation from E. coli 
Single E. coli colonies were picked and cultured with LB-selection medium at 37°C 
over night. Then plasmids were isolated using QIAGEN Plasmid Midi, Maxi or Mega 
Kits following the supplier’s instructions. 
2.3.2.2. DNA sequencing and sequence analysis 
Sequencing was performed by GENEART (Regensburg, Germany). Database 
searches in GenBank were performed using web based sources of NCBI (URL: 
http://www.ncbi.nlm.nih.gov). 
2.3.2.3. Electrophoretic Mobility Shift Assay (EMSA) 
To verify the binding of FOXA2 to hALR promoter EMSAs were conducted. Biotin-
labeled probes were purchased from Metabion. First, 10 µl of complementary pairs of 
oligonucleotides (100 pmol) were annealed by incubation at 95°C for 10 min. 
Afterwards, the heat was gradually reduced overnight or until the oligonucleotides 
have reached room temperature. The assays were performed using LightShift® 
Chemiluminescent EMSA Kit following Pierce’s instructions. Briefly, 20 fmol Biotin-
labeled target duplexes ranged in size from 21-25 bp were incubated with 2 µg HepG2 
NE-PER Nuclear Extract. The binding reactions were supplemented with 2,5% 
glycerol, 50 ng/µl poly (dI•dC) and 0,05% NP-40. For supershift assays, 5 and 10 µg 
anti-FOXA2 antibodies were added to the reaction and incubated for 20 min at room 
temperature. After adding 5 µl of 5x Loading Buffer to each 20 µl binding reaction, 
probes were loaded onto 6% Polyacrylamide gel. After electrophoresis, the binding 
reactions were transferred onto a nylon membrane and cross-linked using 
transilluminator 312 nm for 15 min. The biotin end-labeled DNA is detected using the 
streptavidin-horseradish peroxidase conjugate and the chemiluminescent substrate. 
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2.4. Bacterial culture 
Bacterial growth medium 
Liquid cultures were grown in LB medium with the appropriate antibiotics: 
 
 
 
 
 
 
 to 1 L H2O 
5 g Yeast extract 
10 g Bacto tryptone 
10 g NaCl 
LB medium  LB-agar plates 
to 1LH2O 
5 gYeast extract 
10 gBacto tryptone 
10 gNaCl 
15 gAgar 
 
 
autoclave, cool to 50°C and add the appropriate antibiotics. Pour the LB-agar solution 
into 10 cm Petri dishes and store at 4°C. 
Cultivation of E. coli 
E. coli cultures were cultivated either on LB-agar plates or in liquid LB-medium 
overnight at 37°C in an incubator. Bacterial cultures were obtained by inoculating a 
single colony or suspension of bacteria from a glycerol culture into LB-medium. Liquid 
cultures were incubated in a shaker at 37°C and 240 rpm overnight. It is necessary to 
add an appropriate antibiotic (Ampicillin; 100 µg/ml or kannamycin 30 µg/ml) to select 
the bacteria containing the specific plasmid. 
Glycerol stocks 
For long-term storage at -80°C, E. coli cultures were permanently stored in glycerol 
stocks. To achieve this, 5 ml from the bacterial culture were centrifuged at 300 g for 
5 min. Afterwards, the supernatant was discarded, and the pellet was resuspended 
with 1 ml mixture of LB-medium and sterile glycerol (1:1), filled in a cryo-tube, shock 
frozen in liquid nitrogen and stored at -80°C. 
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2.5. Animal models 
Experimental procedures were approved by the institutional Animal Care and Use 
Committee of the University of Regensburg and the regional authorities. Ten-week-old 
female athymic nude mice NMRI (nu/nu) mice with a mean body weight of 30 g were 
used, 6 of each for mock and ALR expressing HepG2 cells. In brief, 1 x 106 cells were 
harvested, washed twice with PBS and injected subcutaneously into the peritoneal 
cavity of nude mice. After 21 days the formed tumours were taken out and stored at 
-80°C for subsequent analysis. 
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1. Analysis of ALR expression 
1.1. Expression of ALR in regenerating livers 
Liver regeneration after partial hepatectomy involves initiation of proliferation of 
remaining parenchymal cells and is an excellent in vivo model depicting controlled 
hepatocellular growth. In addition, there are other injury models including liver fibrosis 
and hepatic fat accumulation which affect the liver and might trigger the hepatic 
regeneration. All these models represent useful tools for studying signaling 
molecules and factors that are involved in the process of liver regeneration. 
Therefore, distinct experimental injury models were used to analyze the expression 
levels of ALR in the liver and to find out whether ALR expression is regulated during 
liver regeneration. Thus, total RNA was isolated from livers after hepatectomy and 
other models including hepatic fibrosis and liver fat accumulation. The results of the 
quantitative real-time reverse transcription PCR (RT-PCR) showed that ALR 
expression in rats rose shortly after the injury (3,64 ± 1,04 FC) 12 h post-operation 
over control (Fig. 10A). In contrast, the level of ALR mRNA in mouse liver 
continuously increased to about 4,99 ± 0,85 fold over control after 72 hours post-
hepatectomy (Fig. 10B). We further investigated the expression of ALR in additional 
models of liver injury like bile duct ligation (BDL) or after CCl4 treatment. Both models 
have been shown to induce liver fibrosis in animal models 103,104. Figure 10C shows 
enhanced expression of ALR comparing to the control group in response to the injury 
induced by BDL. Further, the CCl4 model demonstrated moderate increase of ALR 
expression which began to rise up to 24 hours after treatment and returned to the 
near-basal expression at 96 h after treatment (Fig. 10D). Another hepatic injury 
model like fatty liver was also used to investigate whether the expression of ALR is 
regulated. Therefore we used two mouse models in which two different diets were 
applied. In particular, “methionine-choline deficient” diet (MCD) was applied 3 weeks 
to mice and “Paigen” diet was applied 12 weeks. Liver tissues were collected, total 
RNA was isolated and the expression of ALR mRNA was measured using qRT-PCR 
(Fig. 10E and F). Both diets caused hepatic lipid accumulation in mice associated 
with different stages of inflammation and revealed higher expression of ALR 
compared to the control group. Taken together, the hepatic tissue damage in all 
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investigated models increased the expression of ALR indicating that ALR could be 
potentially involved in the process of hepatic regeneration. 
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Fig. 10: Quantification of ALR mRNA levels in hepatic tissue after liver injury using 
qRT-PCR. A) Expression of ALR in rat livers undergoing 70% hepatectomy (n=4 animals per 
time point) compared to sham operation (n=2 animals per time point) or B) ALR expression 
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over time postoperation in hemihepatectomized mice. Expression of ALR in response to the 
injury induced by BDL (C) or with CCl4 (D). Expression of ALR in fatty livers of mice fed with 
MCD-diet (for 3 weeks) (E) or paigen-diet (for 12 weeks) (F). Endogenous 18S ribosomal 
RNA was amplified and used as internal control. 
1.2. Expression of ALR in parenchymal liver cells 
To monitor ALR transcription in parenchymal mammalian liver cells, expression 
levels of ALR in primary human hepatocytes (PHH) and hepatoma cells were 
examined using qRT-PCR. Interestingly, ALR expression in proliferative parenchymal 
hepatic cell lines (hepatoma cells) was approximately 3-4 fold higher, peaking in 
HepG2 cells with 15 fold increase over ALR expression in quiescent primary human 
hepatocytes (Fig. 11). As shown in Fig. 11, we found that ALR expression is lower in 
PHH than in hepatocellular cell lines. 
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Fig. 11: Total mRNA levels of ALR in hepatic parenchymal cells. ALR mRNA expression in 
hepatoma cell lines and PHH are quantified by densitometric analysis. Endogenous 18S 
ribosomal RNA was amplified to normalize the amount of ALR mRNA. 
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1.3. Expression of ALR in human HCC tissues 
Next we aimed to investigate the expression pattern of ALR in samples of malignant 
hepatocellular carcinoma compared to normal liver tissue. Therefore, total RNA was 
extracted from eight paired samples of HCC tissues and the corresponding normal 
liver tissue and analyzed by qRT-PCR. In five out of 8 cases, ALR mRNA expression 
was higher in HCC tissues than in the corresponding non-malignant liver tissue 
adjacent to the tumour (samples number 2-4 and 6-7) (Fig. 12). In two samples, ALR 
expression in HCC tissues was nearly same as those in the adjacent normal tissues 
(samples number 5 and 8), but in one case, ALR expression in HCC tissue was lower 
than that in adjacent healthy tissue (sample number 1). The expression of ALR was 
considered as increased when the expression ratio in tumor/normal tissue was 
greater than 1,5. These findings are consistent with our recent results of an 
immunohistochemical study which demonstrates that malignant liver tissues exhibit 
enhanced ALR expression compared to non-malignant adjacent tissue (manuscript in 
preparation). 
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Fig. 12: ALR expression in tissue samples from patients with HCC compared to the 
surrounding non-affected tissue. Eight paired samples of HCC tissues and the corresponding 
normal tissues adjacent to the tumor were analyzed by qRT-PCR and densitometric analysis. 
Annotation T designate the HCC tissues and N corresponds to the paired adjacent healthy 
tissues. Expression of the housekeeping gene 18S ribosomal RNA serves as an internal 
control. 
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2. Regulation of ALR expression 
2.1. Liver specific cytokines and growth factors 
Hepatocytes rarely divide and are normally in a resting G0 state. After liver injury, all 
hepatic cells undergo transition into G1 phase (initiation state) under the control of 
pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6. Once the cells have been 
initiated, progression through the cell cycle requires continued stimulation by growth 
factors such as HGF, EGF, KGF and PDGF. As described in section 1.1 ALR is 
upregulated in different models of liver injury and therefore we investigated if factors 
known to be involved in responses to liver injury affect ALR expression. More 
specifically, we wanted to assess the involvement of different cytokines and growth 
factors, related as responses in diseased livers, in regulating ALR expression. 
Therefore, primary human hepatocytes and hepatoma cells were treated with 
cytokines (TNF-α, IL-1 and IL-6) and growth factors (HGF, EGF, KGF and PDGF). 
Cells were harvested 24 h after stimulation, and total RNA was isolated and analyzed 
by qRT-PCR. We found that growth factors and other co-mitogens had no significant 
effect on ALR mRNA expression (Fig. 13A). Interestingly, stimulation of PHH with 
cytokines IL-1 or IL-6 for 24 h led to enhanced expression of ALR (Fig. 13B). ALR 
levels were induced after stimulation with IL-1 (2,23 ± 0,09 FC) or with IL-6 
(2,37 ± 0,14 FC) over control (Fig. 13B). In contrast, TNF-α could not significantly 
regulate the expression of ALR. 
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Fig. 13: Regulation of ALR expression by cytokines and growth factors. A) Real-time 
RT-PCR determinations of ALR mRNA expression after stimulation with growth factors in 
PHH (open bar) and HepG2 cells (filled bar) for 24 h. B) The expression of ALR in PHH after 
exposure to IL-1, IL-6 and TNF-α for 24 h. C) The effect of Kupffer cell conditioned-medium 
with or without stimulation with LPS for 12 h and 24 h. 
Since non-parenchymal cells (NPC) and particularly Kupffer cells (liver-resident 
macrophages) are the main source of cytokines (IL-1 and IL-6) in the liver, we 
performed an experiment in which Kupffer cells were stimulated to secrete cytokines. 
We cultured Kupffer cells in the absence and presence of LPS (10 ng/ml or 10 µg/ml) 
which has been shown to stimulate Kupffer cells for 12 and 24 hours. Afterwards, the 
supernatants were collected and used as conditioned medium to stimulate PHH. 
Total RNA was analyzed for ALR expression and results are shown in Fig. 13C. 
Interestingly, we found that Kupffer cell conditioned-medium could not affect the 
expression of ALR, assuming that Kupffer cells in addition may release other factors 
which may inhibit the expression of ALR. 
To proof whether stimulation of PHH with cytokines IL-1 and IL-6 leads to enhanced 
protein expression of ALR and to confirm the qRT-PCR, Western Blot analyses were 
performed. Cells were treated for 24 h with cytokines (IL-1α, IL-1β and IL-6), and 
results are presented in Fig. 14. IL-1α and IL-1β are pleiotropic cytokines which are 
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mainly produced by Kupffer cells 105,106 and affect inflammation and immune 
responses 107,108. IL-1α slightly induced ALR protein expression while IL-6 treatment 
resulted in a significant higher expression of ALR protein compared to control. In 
contrast, culturing of the cells in the presence of IL-1β results in reduction of ALR 
protein levels (Fig. 14). Therefore we summarize that liver specific growth factors 
have no impact on ALR expression, but cytokines involved in initiating liver 
regeneration such as IL-6 induce ALR expression. On the other hand, it seems that 
IL-1β resembles an inhibitory factor in ALR regulation. 
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Fig. 14: ALR protein expression after stimulation with IL-1α, IL-1β and IL-6 in PHH. Primary 
human hepatocytes were stimulated with IL-1α (250 U/ml), IL-1β (250 U/ml) and IL-6 
(30 ng/ml) for 24 h. Western Blot analysis using specific anti-ALR antibodies showing the 
expression of ALR-homodimers under non-reducing conditions. The protein expression of 
ALR was measured by densitometric analysis. 
2.2. Analysis of ALR promoter: 
Putative transcription factor binding sites 
Besides cytokines and growth factors, differentially expressed transcription factors 
during liver regeneration play a pivotal role in the regulation of the regenerative 
process. As described in section 2.1, hepatocytes stimulated with IL-6 revealed an 
increase of mRNA and protein expression of ALR compared to resting hepatocytes. 
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The next step was to find out what kind of transcription factors may regulate the 
expression of ALR. The full-length cDNA of ALR consists of around 2,5 kb, located 
on chromosome 16, and is organized in 3 exons with three potential ATG start 
codons in exon 1. Preliminary insights into putative regulatory elements of the ALR 
promoter were obtained by data bank searches of the genomic 5'-flanking region. In 
order to investigate potential transcription factors involved in the regulation of ALR 
expression, we performed promoter studies analyzing transcriptional regulation of 
ALR. Sequence analysis of a fragment (-733 to +502 bp from start codon) of ALR 
promoter by software search tools (TRANSFAC, Tfsearch and TESS) revealed that 
24 putative responsive elements are located in the regulating sequence of ALR 
(Table 1). 
Table 1. Putative transcription factors which may transactivate ALR promoter. 
Program Transcription factor 
Transfac Tfsearch TESS 
FOXA2 x 4 - - 
IL-6 RE-BP - - x 2 
C/EBPβ x 4 - - 
NF-кB - - x 2 
SP1 - x 3 x 53 
HNF-4α1 - - x 2 
YY1 x 1 - x 1 
AP-1 x 7 - x 1 
AP-2 - x 2 x 6 
AP-4 - - x 2 
CACCC-binding factor - - x 2 
C/EBPα - - x 1 
GATA-1 - x 2 x 1 
GCF - - x 10 
GCMα - - x 1 
HSF - x 14 - 
NF-1 x 16 - x 1 
Oct-1 - - x 1 
RAR-α - - x 1 
RAR-β - - x 1 
RXR-α - - x 1 
RXR-β - - x 1 
TFIID - - x 1 
USF x 6 - - 
IV. Results 
 
61
Although promoter analysis revealed a putative NF-кB binding site, our previous 
studies have demonstrated that stimulation with TNF-α, an inductor of NF-кB 
activation, has no effect on the expression of ALR. Therefore, we assumed that 
NF-кB, might not be involved in the regulation of ALR. As shown in table 1, 
hepatocyte nuclear factor-3 β, also termed Forkhead box A2 (FOXA2), has 4 putative 
binding sites. This finding is in agreement with the observation 100 that increased 
levels of FOXA2 are accompanied by induced hepatic ALR expression in mice. We 
further identified other transcription factor binding sites located in the promoter, like 
IL-6 response element binding protein (IL-6 RE-BP) and CCAAT/Enhancer binding 
protein beta (C/EBPβ) which might be involved in mediating the signal transduction of 
IL-6 (Fig. 15). 
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Fig. 15: Promoter sequence of human ALR. Consensus binding sites are underlined. The 
transcribed sequence is printed in bold, and the ATG transcription start codons are shown in 
red and italics. The red arrows indicate the primers used to amplify the genomic DNA. ARE, 
C/EBPβC/EBPβ
TATGAGTGTGAGTCCTTGTTTTTTTTTCCTGTCTTGACCACTGGATTATGAACAGAGAAGGTCAG
GAACAGAATTGTGTTCCCTGCTCTGCCCAGCACTTGGAACAGCGCTTGGAACAGAGCGGTCACTGCG
AATAATAGCGGAATGGATAAATGAACGCAAGGAGGCACAGGAATCCCAGAGGCCGCTCCAACCGG
AGCCCGACCCCTCATCCCAGGCTCTAGGATCCGCGACAGCCGGCGAGGGGCGCCAGGGAGCCCAA
GCACGCGCCAACCCTCTGCGGCCGCGCCGCGCCCTGCGTTGCCAGACGCCCGTTGCCATGGCGCC
GGAGGGGACAAGAGCCCAGGACCCTAGCGCGCGCCGCAATCTGTGCGGTCACGCCCGGCCCGCG
TGAGAGAGCGCTTGGCAGCCAGCGGGTGGACGCGCCCCTCAGCGGAGGGCACAAAGCCTGGCCGC
GCACGCAGGACACTCAGAACGGAGCGATGGGGACGTCGCGGGCCGCAACACGGACTTTGCCTGG
TGTCAGCTCGGGTCCACAGCGCGGCCGAGGCGCACCTTGCGCCACACACTGCTCTTTTACTGGAGA
GCGGGACGGCCGCCACGGACGGCGCAACCCCTGCGTGCGCCGCGGATCGACGCCTGAGGGCGC
GCAGGGTCCGACCCTCCTGCTCCGTCCCCGCCCCTGTCCTCGGGCCCGGCCAGCGCGCGGCCTC
GGCTCCGCCTCCACACGGGCCCGCAAGCAGGCACCGCCCCCGACTCTGCCCCCAGCCCCGGCTCG
GCCCGGCCCCCGCGAGCACGGCGCGCGCCTCCGGCTCCTGTGGCCGCGCGCTGGCCTGGAGGCT
ACCTGGAGGCTCATCTGGAGGCCGAGCTGACCCGGCAGGCCTTGCGCGGGCAAC GCGGCGCC
GGCGAGCGGGGCCGCTTCCACGGCGGGAACCTCTTCTTCCTGCCGGGGGGCGCGCGCTCCGAGA
ACGACCTGGCGACCGACGCGCGGGGCCGGGGCGCGGGGCGGAGAGACGCGGCCGCCTC
GCCTCGACGCCAGCCCAGGCGCCGACCTCCGATTCTCCTGTCGCCGAGGACGCCTCCCGGAGGCG
CCGTGCCGGGCCTGCGTCGACTTCAAGACGTGG CGGACGCAGCAGAAGGTGCAGTTCCCTGC
ATT GCCCCGCGCAGCCCCTGTCCCCGCCCCCGCCCAGGTACCCCGGCAGAGCTTCCC
GGTTGCCTGTCCCTGAACCTTGCCCCCCGGGTAGGCCCGGCCTTACAGCCTTCATCCGCGCGTGG
GGATCGTCTGCAGGACTTTGGCCGGAGTCCAGTGGGCCACCGGCTGGGCCGTACAGTGGGGAG
TTTGGGCGCCTTTGTTCGGAGAATGAACTCACTCTCGGTCGGCCTGCTTCCGCAGCGGGACACCAA
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antioxidant response element; SP1, stimulating protein 1; FOXA2, Forkhead box A2; 
IL-6 RE-BP, IL-6 response element binding protein; HNF-4α, hepatocyte nuclear factor 4α; 
YY1, ying yang 1. 
A lot of prominent transcription factors have been found by our promoter analyses, 
which may play an important role in regulating ALR. Hepatocyte nuclear factor-4 
alpha (HNF-4α) has different potential binding sites in the promoter sequence of 
ALR. It has been shown 88 that HNF-4α regulates the expression of ALR and that 
overexpression of HNF-4α in HepG2 cells led to a dramatic repression of the 
promoter activity of ALR. The same authors demonstrated that SP1 (Stimulating 
Protein-1) activates the basal expression of ALR in hepatoma cells. On the other 
hand, Zhao et al. 86 reported that the TATA-box less core promoter of ALR could not 
be regulated by AP-1, and that YY1 and RNA polymerase might be involved in the 
regulation of ALR promoter. 
Based on this prediction, promoter regions of 938 bp and 1236 bp (Fig. 16) were 
subcloned into pGL2-Basic vector, a promoterless luciferase reporter plasmid, and 
used for further investigations. 
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Fig. 16: Schematic diagram showing the structure of the hALR gene and the construction of 
hALR promoter constructs. ALR promoter constructs (construct 1: -733 to +240 bp, and 
construct 2: -733 to +502 bp) were subcloned into the promoterless pGL2-Basic vector. 
2.3. Impact of FOXA2 on ALR expression 
Both promoter constructs introduced in Fig. 16 have been used to investigate the 
promoter activity using luciferase assays. We have found that the basal activity of 
promoter construct 1 (-733 to +240 bp), Pro 1, was 8 fold and promoter activity of 
construct 2 (-733 to +502 bp), Pro 2, was 14 fold higher over the control in HepG2 
cells (Fig. 17). This finding suggests the presence of regulatory elements located in 
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these promoter regions. The Pro 2 construct reveals higher promoter activity than 
Pro 1 construct indicating the presence of important response elements in the region 
between +241 and +502 bp. Figure 15 displays potential binding sites for FOXA2, 
IL-6 RE-BP, CEBP/β and HNF-4α in the sequence of Pro 2. In a recent study, 
Hughes et al. have shown that in a transgenic mouse model for FOXA2 increased 
expression levels of ALR were observed 100. Furthermore, a nearly perfect FOXA2 
consensus site was identified in the Pro 2 construct. Therefore, we intented to 
investigate the potential regulatory role of FOXA2 on the expression of ALR, and 
tested both reporter constructs Pro 1 (-733 to +240 bp) and Pro 2 (-733 to +502 bp) 
for their response to FOXA2. Both constructs were transfected to HepG2 cells 
(human liver cancer cells), H1299 cells (human lung cancer cells) and Caco-2 cells 
(human colorectal cancer cells). After 24 hours the cells were lysed and the 
luminescence signal was measured. Firefly luciferase activities were normalized to 
the Renilla luciferase activity of pRL-TK co-transfected vector as internal control. 
Reporter gene assays demonstrated strong activity of the promoter construct Pro 2 
(2,69 ± 0,10) x 104 RLU, and this activity could be further induced in HepG2 cells by 
o-transfection with a FOXA2 expression plasmid (8,29 ± 0,45) x 104 RLU (Fig. 17). 
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Fig. 17: Transactivation of ALR promoter by FOXA2. ALR constructs Pro 1 and Pro 2 were 
transfected wih 0,5 µg (filled bar) or without (open bar) FOXA2 expression plasmid in three 
cell lines of different origin. In contrast to H1299 cells (lung cancer cells) and Caco-2 cells 
(colorectal cancer cells), HepG2 cells (liver cancer cells) revealed higher activit
HepG2 H1299 Caco-2 
pGL2 Pro1 Pro2 pGL2 Pro1 Pro2 
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Interestingly, FOXA2 was able to enhance the activity of ALR in hepatoma cells e.g. 
HepG2, compared to H1299 cells and Caco-2 cells. Subsequently, we investigated 
the effect of different amounts (0,1 and 0,5 µg) of FOXA2-pcDNA3.1 expression 
plasmid on the activity of ALR promoter in HepG2 cells. While no change in the 
activity of the construct Pro 2 (0,45 ± 0,00) could be found after using 0,1 µg FOXA2, 
0,5 µg FOXA2 transactivates the promoter of ALR in HepG2 cells resulting in 
increased activity of the construct Pro 2 (2,54 ± 0,29) x 104 RLU over the control 
(0,78 ± 0,00) x 104 RLU (Fig. 18). Based on these observations we assume that 
FOXA2 needs a hepatic environment to specifically regulate ALR expression in the 
liver. 
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Fig. 18: Transactivation of ALR promoter using different amounts of FOXA2. Reporter-gene 
constructs were transfected into HepG2 cells with different amounts of FOXA2 expression 
vector. In contrast to 0,1 µg, 0,5 µg FOXA2 enhanced the luciferase activity of Pro 2 nearly 
3,5 fold over the control indicating the presence of FOXA2 response element in the Pro 2 
sequence. 
Based on the finding that FOXA2 exclusively activates construct Pro 2, we 
summarize that the responsiveness of ALR promoter to FOXA2 is due to the FOXA2 
response element and this binding site is located within the first intron of ALR gene. 
To gain more insight whether this putative FOXA2 response element could bind 
FOXA2 we performed Electrophoresis Mobility Shift Assays (EMSA). 
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Oligonucleotides representing the FOXA2 element were incubated with nuclear 
extract of HepG2 cells and binding of the nuclear complex to the FOXA2 consensus 
oligonucleotide was analyzed (Fig. 19A, lane 3). The protein-DNA complex is specific 
for the FOXA2 binding site, because co-incubation of 200 fold excess of unlabeled 
oligonucleotides completely abrogated its formation indicating that nuclear proteins 
binding FOXA2 oligonucleotide also recognize the unlabeled FOXA2 consensus 
sequence (Fig. 19A, lane 2). Furthermore, incubation with 5 µg specific anti-FOXA2 
antibody significantly reduced the formation of the FOXA2-DNA complex (Fig. 19A, 
lane 4). When the nuclear extracts were incubated with 10 µg anti-FOXA2 antibody 
(Fig. 19A, lane 5), the complex disappeared confirming the specific binding of FOXA2 
to ALR promoter. FOXA2-DNA complex was quantified by densitometric analysis 
(Fig. 19B). 
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Fig. 19: Binding of FOXA2 to FOXA2 response element in the ALR promoter. A) Labeled 
oligonucleotides representing the FOXA2 site in the wild type ALR promoter (lanes 2-5) were 
incubated with 2 µg of nuclear extracts derived from HepG2 cells cultured in the absence 
(lanes 2, 3) or presence of (5 µg and 10 µg) anti-FOXA2 antibodies (lanes 4, 5), respectively. 
200 fold molar excess of cold FOXA2 consensus oligonucleotides were added in lane 2. 
Lane 1 represents the free probe. The protein-DNA complex is indicated by an arrow. B) 
FOXA2-DNA complex (from A) was quantified by densitometric analysis. 
Normally, when an antibody recognizes and binds to its target protein, the DNA-
protein complex becomes larger and migrates more slowly than DNA-protein 
complex without antibody. This phenomenon is referred to as a supershift and 
indicates the specific binding of the antibody to its target protein. In addition, the 
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disappearance of the DNA-protein complex exhibits further form of supershift. In our 
study, the disappearance of the specific EMSA band may be due to the fact that the 
specific anti-FOXA2 antibody masks the epitope in the FOXA2 protein structure 
which is required for binding to its recognition sequence at the ALR promoter. This 
may explain the abrogation of the formation of protein-DNA complex and therefore 
the disappearance of the specific EMSA-complex by using specific antibodies. The 
disappearance of EMSA-complex is a form of supershift which has been described in 
several publications 109,110. We showed that FOXA2 specifically binds to its binding 
site and therefore may regulate the expression of ALR. 
2.4. Effect of IL-6 RE-BP and C/EBPβ on ALR promoter activity 
As described in section 2.3, the first intron of ALR gene shows high ability to get 
activated suggesting the presence of regulatory elements located in this promoter 
region. Therefore, we analyzed the sequence of the first intron of ALR gene using 
different transcription factor prediction softwares as shown in Fig. 15 and table 1. In 
addition to the binding site for FOXA2, we found two putative response elements for 
IL-6 and two binding sites for C/EBPβ (Fig. 20). 
 
 
 
 
 
 
 
 
 
 
Fig. 20: Promoter sequence of human ALR between exon 1 and exon 2. Consensus binding 
sites are underlined. The transcribed sequence is printed in bold and the ATG transcription 
start codon is shown in red and italics. The red arrows indicate the primers used to amplify 
the genomic DNA. 
We wanted to know whether the observed regulation of ALR by IL-6 (see Fig. 13B, 
and Fig. 14) is mediated by IL-6 RE-BP, and therefore we performed EMSA assays. 
HepG2 cells were treated with 30 ng/ml IL-6 for 15 min and the subsequently nuclear 
proteins were incubated with IL-6 RE oligonucleotides. No specific binding of nuclear 
proteins to the IL-6 RE consensus was observed (Fig. 21A). This indicates that 
IL-6 RE located next to C/EBPβ binding site could not directly bind to the IL-6 RE 
C/EBPβC/EBPβ
........GTGCCGGGCCTGCGTCGACTTCAAGACGTGGATG
TCT
CGGACGCAGCAGAAGGTGCAGTTCCCTGC
CCGATT CCCAGCCCCGCGCAGCCCCTGTCCCCGCCCCCGCCCAGGTACCCCGGCAGAGCTTCCC
AGGGTTGCCTGTCCCTGAACCTTGCCCCCCGGGTAGGCCCGGCCTTACAGCCTTCATCCGCGCGTGG
GTTGGATCGTCTGCAGGACTTTGGCCGGAGTCCAGTGGGCCACCGGCTGGGCCGTACAGTGGGGAG
CTTTGGGCGCCTTTGTTCGGAGAATGAACTCACTCTCGGTCGGCCTGCTTCCGCAGCGGGACACCAA
GTTTAGGGAGG…………
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sequences (5’-TTCCCAG-3’). Further, it seems that IL-6 may not regulate the 
expression of ALR via the IL-6 response element binding protein (IL-6 RE-BP) 
located in the vicinity of C/EBPβ binding site in the first intron of ALR gene. Using 
EMSA technique, no transactivation of the promoter was observed when using the 
potential C/EBPβ site demonstrating that C/EBPβ is not able to bind to its potential 
binding site (5’-TTGCC-3’) located in the first intron (Fig. 21B, lane 3). Additionally, 
we could not observe any C/EBPβ-DNA complex when the HepG2 cells were 
simultaneously treated with IL-6 (Fig. 21B, lane 4). Further, we performed luciferase 
assays investigating the effect of C/EBPβ expression plasmid on the activity of ALR 
promoter in the absence and presence of 30 ng/ml IL-6. No changes in the promoter 
activity could be shown after transfection of C/EBPβ (data not shown) indicating that 
C/EBPβ could not transactivate the promoter of ALR. Based on this finding, we 
hypothesize that C/EBPβ plays no direct regulatory effect on the expression of ALR 
and that C/EBPβ is not involved in mediating the IL-6 regulation of ALR expression. 
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Fig. 21: EMSA experiments with either IL-6 RE (A) or C/EBPβ (B) consensus. Assay was 
performed with 2 µg nuclear extracts from cultured HepG2 cells in the absence (lane 3) or 
presence of IL-6 (30 ng/ml) (lane 4). 200 fold molar excess of cold consensus oligo-
nucleotides were added in lane 2. Lane 1 represents the free probe. IL-6 RE-BP, IL-6 
response element binding protein; C/EBPβ, CCAAT/Enhancer Binding Protein beta. 
2.5. Synergistic effect of FOXA2 and IL-6 on ALR promoter 
Since the FOXA2 binding site is located next to IL-6 responsive element, we 
investigated whether the FOXA2 binding site (5’-ATTTCTC-3’) and the IL-6 RE 
(5’-TTCCCTG-3’) may interact, or whether this potential interaction is necessary for 
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the transactivation of ALR promoter through IL-6. To elucidate the putative combined 
effect of FOXA2 and IL-6 on the activity of ALR promoter, we performed luciferase 
assays using 1 µg of the ALR promoter construct 2 and 0,5 µg of the expression 
plasmid of FOXA2 in the absence or presence of 30 ng/ml of IL-6. Promoter activity 
of ALR was induced after IL-6 stimulation and this induction was able to be further 
enhanced when the cells were co-transfected with FOXA2 (Fig. 22). 
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Fig. 22: Enhancement of ALR promoter activity by IL-6 and FOXA2. 1 µg ALR-pGL2 was 
transfected with or without 0,5 µg FOXA2-expression plasmid into HepG2 cells using 
siPORT-XP1. 30-36 hours after transfection, cells were serum-starved overnight and IL-6 
(30 ng/ml) was added for 15 min. After stimulation, cells were harvested and cellular lysates 
were analyzed for luciferase expression using a luminometer. 
To confirm the luciferase results and to verify the synergistic effect of IL-6 and 
FOXA2, EMSA was performed. Oligonucleotides contained either FOXA2 or IL-6 
binding elements and nuclear extracts isolated from HepG2 cells were incubated for 
40 min in the absence or presence of IL-6 (30 ng/ml). We observed that the binding 
of FOXA2 to the DNA was enhanced after stimulation with IL-6 (Fig. 23, lane 4) 
compared to the non-stimulated HepG2 nuclear extracts (Fig. 23, lane 3). These 
results underline an important effect of IL-6 transactivation for the binding of FOXA2 
to ALR promoter. On the other hand, a binding of transcription factors to the IL-6 RE 
is not involved in FOXA2 interaction (Fig. 23, lanes 5-8). Thus, it seems that IL-6 RE 
is not required for a correct positioning of FOXA2 to its recognition site. Based on 
these findings, we suppose that IL-6 activates some other transcription factors which 
may act as co-activators for FOXA2. 
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Fig. 23: Enhancement of FOXA2 binding to ALR promoter upon stimulation with IL-6. The 
oligonucleotide which contains FOXA2-RE binds FOXA2 (lanes 3, 4), whereas the 
oligonucleotide which contains IL-6 RE does not (lanes 7, 8). 2 µg nuclear extract isolated 
from HepG2 cells in the absence (lanes 3, 7) or presence of IL-6 stimulation (30 ng/ml for 
40 min) (lanes 4, 8) were used. Cons., consensus. 
Additionally, we investigated the expression of ALR protein after stimulation with IL-6 
and FOXA2 (Fig. 24) by Western Blot and densitometric analysis. As shown in 
Fig. 24, stimulation with IL-6 (30 ng/ml) as well as with FOXA2 (0,5 µg) enhanced 
levels of ALR protein. Taken together, both IL-6 and FOXA2 could induce the protein 
expression of ALR. 
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Fig. 24: ALR protein expression after stimulation with IL-6 and FOXA2. Western Blot 
analysis using specific anti-ALR antibodies showing the expression of ALR-monomers 
(15 kDa) and quantification of the protein bands by densitometric analysis. 
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3. Overexpression of ALR 
3.1. Generation of ALR-overexpressing HepG2 cells 
Liver regeneration is a process which involves various cell biological processes as 
cell activation and proliferation of hepatic cells 11. Some of these processes including 
cell growth and proliferation are common to hepatocancerogenesis. Furthermore, we 
have demonstrated an up-regulation of ALR expression in regenerative processes as 
well as in hepatocellular carcinoma 81. To gain more insight into the impact of ALR on 
cellular growth and potential tumorigenicity, we stably overexpressed ALR in HepG2 
cells. We designed an ALR-expression plasmid and subcloned the full-length cDNA 
of human ALR (375 bp) which encodes 125 amino acid protein (15 kDa) (Fig. 25) into 
an expression vector pcDNA3.1 under the control of the cytomegalovirus (CMV) 
promoter. The ligated plasmid was then sequenced to proof the presence and the 
direction of the insert. 
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Fig. 25: Design of an ALR-expression plasmid. The cDNA sequence of ALR (375 bp) is 
printed in bold and restriction sites are underlined. Both ATG transcription start codon and 
TAG stop codon are shown in red and italics. 
After successful transfection of HepG2 cells with the expression vector, ALR-
overexpressing cells were selected due to G-418 resistance over a period of two 
weeks. Cells bearing a vector without insert served as negativ control (mock). To 
verify whether the stably transfected HepG2 cells do overexpress ALR, real-time 
RT-PCR analysis was performed for all 24 selected clones (data not shown). Among 
all screened clones, two clones (named clone 1 and clone 2) have been choosen to 
AATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGA
CCC GGACGCAGCAGAAGCGGGACACCAAGTTTAGGGAGGACTGCCCGCCGGATCGCGAGGA
CTGGGCCGCCACAGCTGGGCTGTCCTCCACACCCTGGCCGCCTACTACCCCGACCTGCCCACCCCA
AACAGCAGCAAGACATGGCCCAGTTCATACATTTATTTTCTAAGTTTTACCCCTGTGAGGAGTGTGCT
AAGACCTAAGAAAAAGGCTGTGCAGGAACCACCCAGACACCCGCACCCGGGCATGCTTCACACAG
GGCTGTGCCACCTGCACAATGAAGTGAACCGCAAGCTGGGCAAGCCTGACTTCGACTGCTCAAAAG
GGATGAGCGCTGGCGCGACGGCTGGAAGGATGGCTCCTGTGAC AATTCTGCAGATATCCAGCA
AGTGGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAG
TGC
ATGC
TAG
T7 Promotor HindIII
NotI pcDNA3.1/BGH reverse priming site
NheI
hALR
EcoRV
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be used in all following experiments. Figure 26A shows ALR mRNA expression in 
clone 1 and clone 2 and demonstrated a significantly increased level compared to 
wild type cells and mock-transfected cells. To verify whether the increased mRNA 
levels of ALR lead to enhanced protein expression, ALR protein was analyzed 
performing Western Blot analysis (Fig. 26B). Both ALR-overexpressing HepG2 cell 
clones demonstrated significant increase of ALR protein levels compared to wild type 
and mock cells (Fig. 26B). 
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Fig. 26: Determination of ALR expression in ALR-overexpressing HepG2 cells compared to 
wild type and mock cells. A) Quantitative RT-PCR analysis revealed a strong induction of 
ALR mRNA expression in both cell clones (clone 1 and clone 2), whereas no significant 
change of ALR expression was observed in mock transfected cells. B) Expression of ALR 
protein using Western Blot analysis in non-transfected HepG2 cells (wt), mock-transfected 
HepG2 cells (mock) and stable-transfected ALR-overexpressing HepG2 cells (clone 1 and 
clone 2). The protein expression was quantified by densitometric analysis. 
Further, we attempted to investigate whether overexpression of ALR has an impact 
on the proliferation of hepatoma cells. As shown in Fig. 27, we could not find any 
change in the proliferation curve between ALR-overexpressing HepG2 cells 
compared to mock cells. 
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Fig. 27: Proliferation rate of HepG2 cells upon overexpression of ALR. Cellular growth was 
determined after 24 h, 48 h and 72 h using MTT assay. The value of cell growth of each cell 
type at 24 h was set at 1. Mock, mock-transfected HepG2 cells; clone 1 and clone 2, stable-
transfected ALR-overexpressing HepG2 cells. Assay was performed in triplicate. 
3.2. Tumorigenicity of ALR-overexpressing HepG2 cells 
After we had generated ALR-overexpressing HepG2 cells and in addition to the 
above in vitro data, we investigated the cellular behavior of wild type (wt-HepG2) 
cells and ALR-overexpressing (ALR-HepG2) cells in vivo. We injected 1 x 106 cells of 
clone 1, clone 2 and mock-control subcutaneously into the peritoneal cavity of 
immune incompetent nude mice. One week after injection of hepatoma cells, all mice 
from all groups (n=6) developed tumors. The body weight and tumor size were 
measured for all mice every week. After three weeks mice were sacrificed and 
resulting tumor tissue was snap-frozen and stored for further analysis. In figure 28 
the average of body weight of all groups is shown demonstrating that mice 
xenografted with clone 2 cells have less weight than mice xenografted with clone 1 
cells or mock cells. 
Further, we determined the size of the resulting xenograft tumors after 21 days and 
found smaller tumors derived from clone 2 cells compared to tumors derived from 
clone 1 cells or mock cells (Fig. 29). 
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Fig. 28: Determination of final body weight (after 3 weeks) of mice injected with 
ALR-overexpressing HepG2 cells or mock cells. Average body weight of mice xenografted 
with ALR-overexpressing cells (clone 2) was lower than that of mice xenografted with clone 1 
cells or mock cells, (n=6/group). Data were analyzed using boxplot method. The box contains 
50% of the data. The upper edge of the box indicates the 75th percentile of the data set and 
the lower edge indicates the 25th percentile. The end of the vertical lines indicates the 
minimum and maximum data values. Small rectangles represent the mean value of the data 
and the line in the box indicates the median value of the data. 
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Fig. 29: Size of tumors from ALR-overexpressing hepatoma cells in vivo. Tumour size was 
determined 21 days after injection of 1 x 106 ALR-overexpressing HepG2 cells (clone 1 and 
clone 2) and mock transfected cells (control) into immuno incompetent nude mice 
(n=6/group). Data were analyzed using boxplot method. The box contains 50% of the data. 
The upper edge of the box indicates the 75th percentile of the data set and the lower edge 
indicates the 25th percentile. The end of the vertical lines indicates the minimum and 
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maximum data values. Small rectangles represent the mean value of the data and the line in 
the box indicates the median value of the data. 
The observed differences of mouse total body weight or tumor size might be due to 
different expression levels of ALR (see Fig. 26B). Therefore we determined the ALR 
mRNA levels of the xenograft tumors by qRT-PCR and found very high levels of ALR 
in tumors derived from clone 2 cells but low expression in tumors derived from 
clone 1 cells, where the latter is comparable to ALR levels in tumors derived from 
mock cells (Fig 30). 
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Fig. 30: Quantification of ALR mRNA in xenograft tumor tissue. Total RNA was isolated from 
tumor tissues, reverse-transcribed and determined using LightCycler technology. The results 
were normalized to 18S rRNA. 
Further, immunohistochemical analysis were performed to investigate the protein 
expression of ALR in tumors derived from mock, clone 1 and clone 2 cells (Fig. 31) 
and to confirm the results of qRT-PCR. Results of immunohistochemical analysis are 
shown in Fig. 31 and confirm the finding of the qRT-PCR analysis which showed that 
clone 2 cells overexpress ALR (Fig. 31E, F). In contrast, tumors derived from mock 
cells (Fig. 31A, B) and clone 1 cells (Fig. 31C, D) showed no immunoreactivity for 
ALR. Based on this finding, clone 2 cells were further used in upcoming experiments 
and were renamed as “ALR-HepG2 cells”. 
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Fig. 31: Analysis of ALR expression by immunohistochemistry in tumor tissues. Tumors 
derived from mock cells (A, B) and clone 1 cells (C, D) show comparable low 
immunoreactivity for ALR, whereas clone 2 cells (E, F) revealed more intense immunosignal 
for ALR. 
It is worth to mention that tumors derived from ALR-overexpressing cells displayed 
less-necrotic areas and showed a more epithelial-like cell growth (Fig. 32A) 
compared to wt-HepG2 cells which revealed signs of necrosis (Fig. 32B) and a more 
agressive growth (Fig. 32D). Additionally, less polymorphisms were observed in 
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tumors derived from ALR-HepG2 cells (Fig. 32C), whereas tumors derived from 
wt-HepG2 cells demonstrated atypical mitotic figures, as shown in Fig. 32D. 
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Fig. 32: Analysis of growth behavior of xenograft tumors. Samples of mouse in vivo tumors 
were analyzed by HE-staining and showed for ALR-HepG2 cells (A) a more epithelial-like 
growth compared to ALR low expressing cells indicating necrotic areas (B, arrows). 
Furthermore tumors from wt-HepG2 cells showed atypical mitotic figures (D, arrows), 
whereas ALR-overexpressing tumors demonstrated typical cellular growth (C). 
Based on the observation of different tumor sizes and the cellular growth in vivo we 
may speculate that overexpression of ALR in HepG2 cells attenuate tumorigenic 
growth. 
3.3. Impact of ALR on migration and invasiveness of hepatoma cells 
The finding of a potential influence of ALR on tumorgenicity of hepatoma cells in vivo 
encouraged us to analyze the impact of ALR on motility and potential metastasis. 
Metastasis is a critical step in tumor progression and is a main cause of human 
cancer deaths 111,112. It occurs in a series of multiple steps including tumor cell 
migration, invasion and proliferation 113,114. To elucidate the effect of ALR on the 
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motility of hepatoma cells, migration assays were performed using modified Boyden 
chambers. Briefly, 5 x 104 cells (ALR-HepG2 or wt-HepG2) were seeded with 1% 
FCS-DMEM into inserts with 8 µm filter pores which were either uncoated (migration 
assay) or matrigel-coated (invasion assay). As a chemoattractant 10% FCS were 
used and after 24, 48, 72 h cells were fixed, stained and counted in each field. 
Interestingly, ALR-HepG2 cells reduced cell motility (63,67 ± 16,74 cells/field) 
compared to the wt-HepG2 cells (622,00 ± 74,10 cells/field) after 48 hours (Fig. 33). 
A similar result was observed after performing the invasion assay. ALR-
overexpressing HepG2 cells showed a significantly reduced potential to invade 
(10,97 ± 2,65 cells/field) than wt-HepG2 cells (49,30 ± 6,00 cells/field) (Fig. 33). 
These data suggest that migration and invasion properties of hepatoma cells was 
markedly reduced after expression of ALR. 
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Fig. 33: Impact of ALR on the migration and invasiveness of hepatoma cells. Migration and 
invasion assays using Boyden chambers were performed for 48 hours. The membranes 
were fixed and stained and cells were counted. ALR-HepG2 cells, ALR-overexpressing 
HepG2 cells; wt-HepG2 cells, wild type HepG2 cells. 
These results are in agreement with other data from our laboratory which showed 
that high levels of ALR in HCC tissues are inversely correlated with the invasive 
activities of hepatocellular carcinoma (manuscript in preparation). Based on these 
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findings we hypothesize that ALR might interfere with migration- and invasiveness-
related pathways in hepatocellular carcinoma cells. 
The change in migratory and invasion properties of ALR-overexpressing HepG2 cells 
prompted us to investigate whether ALR influences the cell-cell contact or cell 
adhesion molecules. Therefore, we performed attachment assays 15 min after 
replating of wt-HepG2 cells or ALR-HepG2 cells in 96-well plate. We found that 
ALR-overexpressing HepG2 cells showed significantly induced attachment rates 
(7812,50 ± 2809,02 cells) over those of wild type HepG2 cells 
(3812,50 ± 625,00 cells) (data not shown). Further, to confirm the ability of high 
cellular levels of ALR to modulate cell migration, we performed wound healing 
assays using wt-HepG2 cells and ALR-HepG2 cells over a period of 72 hours 
(Fig. 34). Wild type HepG2 cells showed a significantly faster “wound” closure 
compared to ALR-overexpressing HepG2 cells. Taken together, we assume that ALR 
may regulate adherence and cell-cell contact of the hepatoma cells. 
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Fig. 34: Impact of ALR on the migratory potential of hepatoma cells. Monolayer scratch 
assays were performed with ALR-overexpressing HepG2 cells (ALR-HepG2) and wild type 
HepG2 cells (wt-HepG2) and representative pictures of the areas between scratch fronts 
after 3 days are shown. 
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3.4. Effect of ALR on EMT markers 
Migration and invasion are mainly mediated by specific cell-adhesion molecules. 
Therefore to analyze the molecular background of the observed altered ability of 
migration and invasion we aimed to assess the expression of prominent 
cell-adhesion molecules like the epithelial cadherin (E-cadherin). The family of 
cadherins are Ca2+-dependent proteins which mediate homotypic interaction between 
adjacent epithelial cells, of which E-cadherin is a typical factor. It is known that 
down-regulation or mutation of E-cadherin is frequent in human tumors and often 
occurs during cancer progression 115. In order to investigate the potential regulation 
of E-cadherin by ALR, we seeded wt-HepG2 cells and ALR-HepG2 cells on chamber 
slides and cultured them for 24 hours. Cells were fixed and stained using 
anti-E-cadherin antibody. Interestingly, we observed that wt-HepG2 cells showed no 
immunoreactivity for E-cadherin staining whereas ALR-HepG2 cells demonstrated a 
clear plasma membrane staining (Fig. 35, arrows). 
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Fig. 35: E-cadherin expression in ALR-overexpressing HepG2 cells and in wild type HepG2 
cells. Immunofluorescence analysis shows induced expression of E-cadherin protein on the 
cell membrane in ALR-HepG2 cells (white arrows) compared to wt-HepG2 cells. The rabbit 
IgG isotype control served as a negative control for immunofluorescent staining. 
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In addition, performing Western Blot analysis we could confirm our immuno-
cytochemical result, showing that only ALR-overexpressing HepG2 cells express 
E-cadherin (Fig. 36). 
To analyze the mechanism by which ALR regulates E-cadherin, we first investigated 
the impact of ALR on the expression of the transcription factor SNAIL because 
E-cadherin was found to be directly regulated/repressed by SNAIL. It has been 
shown by others that SNAIL converts epithelial cells into mesenchymal cells by 
directly repressing the expression of E-cadherin 116. In our study we found that ALR 
expression in hepatoma cells down-regulates the expression of SNAIL. On the other 
hand, we investigated that effect of ALR expression on the stability of HIF-1α protein. 
Stability of the hypoxia-inducible factor (HIF-1α) has been reported to be necessary 
and sufficient to suppress E-cadherin expression by inducing the expression of 
transcriptional repressors of E-cadherin 117,118. No changes were observed in the 
levels of HIF-1α protein indicating that elevated intracellular levels of ALR did not 
affect the stability of (HIF-1α) (Fig. 36). 
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Fig. 36: Impact of ALR on the protein 
expression of both E-cadherin and SNAIL 
and on HIF-1α stability. ALR-HepG2 cells 
exhibit induced expression of E-cadherin 
and with reduced expression of SNAIL. 
Whereas ALR expression could not 
influence the stability of HIF-1α. β-actin 
served as intern control.
 
Based on these data, we speculate that ALR up-regulates the expression of 
E-cadherin by reducing the expression of SNAIL. Furthermore, HIF-1α seems to be 
not involved in E-cadherin upregulation by ALR. 
One more feature of EMT is the overexpression and/or activation of the matrix 
metalloproteinases (MMPs), which are main features of tumor progression and are 
associated with invasion, angiogenesis and metastasis. Among them, MMP-3 
(stromelysin-1, Str-1), exerts oncogenic effect and plays an important role by 
triggering EMT in vitro 119 120 and in vivo . In addition, it was reported that MMP-3 can 
activate other MMPs in ECM like MMP-1 which is known to play a critical role in 
invasion and tumor grwoth in the metastatic process 121. Therefore, we additionally 
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investigated the impact of ALR on the expression of both MMP-3 and MMP-1 and 
found that ALR reduces the mRNA expression of both MMP-3 and MMP-1. The 
transcriptional expression of both was inhibited up to 80% in ALR-HepG2 cells 
compared to wt-HepG2 cells (Fig. 37). 
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Fig. 37: mRNA expression of MMP-1 and MMP-3 in wt-HepG2 cells and ALR-HepG2 cells 
by qRT-PCR. ALR-overexpressing HepG2 cells show reduced expression of both MMP1 and 
MMP-3 compared to wt-HepG2 cells. Expression of the housekeeping gene 18S ribosomal 
RNA serves as an internal control. 
Since MMP-3 has been shown to transcriptionally induce the expression of 
SNAIL 122, we hypothesize that ALR attenuates the expression of MMP-3 followed by 
SNAIL inhibition which in turn up-regulates the expression of E-cadherin. 
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The liver possesses a remarkable capacity to regenerate after physical damage or 
injury caused by infections or toxins 5,123. The fascinating ability of the liver to 
regenerate is the effect of cross-talk between cytokines, growth factors and 
hormones which are required for cellular growth and proliferation. The impact of 
many cytokines (IL-1, IL-6 and TNF-α) and growth factors (EGF, HGF and TGF-α) on 
human hepatocytes has been described by several authors 2,11,13,14. These factors 
have been found to be highly expressed upon liver damage and were shown to play 
an important role within the process of liver regeneration 2,124. Recently, the liver 
regeneration associated protein ALR, has received great attention and its role as a 
hepatotrophic factor has been partially clarified. Its has been found that ALR is an 
ubiquitous protein and its hepatotrophic effect as extracellular factor seems to be 
restricted to the liver. This liver-specific effect might be due to a specific receptor, so 
far only found on the surface of hepatocytes and hepatoma cells 27. In addition, ALR 
was found to be a pivotal intracellular survival factor in hepatocytes 125. It was shown 
that transfection of primary rat hepatocytes with antisense oligonucleotides for ALR 
mRNA (long form) resulted in mitochondrial and cellular depletion of ALR, 
accompanied by profound loss of ATP, release of cytochrome c from mitochondria, 
cellular release of LDH and apoptotic/necrotic death of hepatocytes 125. 
Previous ALR expression studies in rat liver revealed a specific detection of ALR in 
the cytosol of hepatocytes and non-parenchymal liver cells 126. However, non-
parenchymal liver cell immunostaining varied and could not be verified in cultured 
cells 126. Furthermore, the authors could not observe increased ALR expression in 
liver tissue after hepatectomy 126. They described rather a decrease in ALR 
expression in hepatic tissue levels accompanied with an increase of ALR serum 
levels 12 h after 70% hepatectomy 126. A controversial finding concerning the latter 
report has been published by others regarding increased ALR mRNA expression 
levels in the remnant liver of a partially hepatectomized rat 12 h post-
operation 67,127-129. In this study, we investigated the expression of ALR in distinct 
experimental models of liver injury induced by different causes. We observed an 
increase in ALR mRNA content in livers with injury caused not only by tissue loss 
(hepatectomy), but also by bile duct ligation (BDL), CCl4 treatment and hepatic lipid 
accumulation (NASH model). Regarding these results we conclude that ALR is part 
of the regeneration process in general, independent of the initial injury, and therefore 
we additionally suggest an important role of ALR in cirrhosis as well as in liver 
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carcinoma 81. This hypothesis is based on the fact that the regeneration process and 
carcinogenesis show many similarities including cellular growth. Repeated 
hepatocyte proliferation during liver regeneration may cause disorder of genes which 
regulate the cell cycle in hepatocytes, therefore favouring HCC development 130. 
Growth factors such as HGF, EGF and TGF-α have been shown to be increased in 
cirrhotic tissues 131-134 and associated with hepato-cancerogenesis 134-137, even 
though the HGF expression in HCC development is controversial 138,139. Our previous 
finding on induced ALR protein expression in cirrhosis as well as in HCC parallel 
these reports 81, since ALR was originally discovered as a hepatotrophic factor with 
mitogenic effect in liver regeneration 140. 
The observation that ALR is differentially expressed during regenerative processes 
raises many questions on its potential regulation by factors known to be elevated 
within these processes. More specifically, we wanted to assess the involvement of 
different cytokines, growth factors and transcription factors, known to be differentially 
expressed/activated in liver regeneration as well as in HCC, in regulating the gene 
expression of ALR. In particular, we aimed to define which cis-acting elements are 
required for transcription of human ALR gene. Thus, promoter analyses were 
performed using different transcription factor prediction softwares. Computer analysis 
of the 5’-regulatory sequences (-733 to +502 bp) of ALR predicts the presence of 
potential binding sites for IL-6 RE-BP, NF-кB, FOXA2, C/EBPβ, AP1, SP1, HNF4α 
and Nrf2. In contrast to previous studies analyzing the promoter sequence only to 
+205 bp (-1222 to +205 bp) 86 we included the first intron of ALR gene in our 
promoter analysis to adress the potential specific regulation of the short form 
(15 kDa) of ALR (initiating ATG, +241 bp). In addition, the regulatory elements and 
potential transcription factor binding sites located within introns have been found to 
play an important role in regulating the expression of target genes 141-146. 
Interestingly, sequence analysis of ALR promoter revealed that the first intron of ALR 
gene exhibits putative binding sites for SP1, FOXA2, IL-6 RE-BP, C/EBPβ and 
HNF-4α (see sections 2.2 and 2.4). 
IL-6 RE-BP, FOXA2 and C/EBPβ are known to be regulated/activated after 
stimulation with IL-6 147,148, while NF-кB has been shown to get activated by 
TNF-α 149. Therefore, we performed several stimulation experiments using various 
cytokines and growth factors. We have found that ALR is regulated neither by growth 
factors which have been used in our experiments nor by TNF-α demonstrating that 
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these factors may not act upstream of ALR. In contrast, we observed that IL-6 
induced ALR gene expression 24 hours after stimulation. Based on the fact that 
Kupffer cells, besides hepatic stellate cells are the main source of IL-6 in the hepatic 
environment, we investigated the expression pattern of ALR in hepatocytes 
stimulated with Kupffer cell conditioned-medium. No change could be observed 
regarding the expression profile of ALR although high amounts of IL-6 were detected 
in the Kupffer cell conditioned-medium. This unexpected result may be explained by 
the fact that in addition to IL-6, Kupffer cells produce several other factors 2,11,16,150,151 
which may negatively modulate the expression of ALR or at least reverse the 
stimulatory effect of IL-6. One of these factors might be IL-1β which is known to have 
anti-proliferative effects on hepatocytes 150,152,153. It has been shown that IL-1β exerts 
a transient inhibitory effect to the IL-6 stimulatory signal 154. The inhibitory action of 
IL-1β on IL-6-inducible gene expression depends on the interruption of the IL-6 signal 
transduction pathway from the cell surface to the nucleus 154,155. The inhibition of IL-6 
cascade might be explained at least by two mechanisms, the dephosphorylation of 
STAT1 and the attenuation of STAT1/STAT3 binding to promoter of target 
gene 154,155. To confirm this hypothesis, we analyzed the protein expression of ALR 
after stimulation with IL-1β and found slightly reduced ALR levels while incubation 
with IL-6 revealed increased ALR protein expression. Taken together, we conclude 
that both IL-6 and IL-1β are involved in ALR gene regulation by enhancing and 
reducing ALR expression, respectively. A similar gene regulation by IL-6 was 
reported for HGF demonstrating several IL-6 RE located in the HGF promoter 156,157. 
These IL-6 response elements have been shown to mediate the stimulatory effect of 
IL-6 on the gene expression of HGF 158. These data underline the mitogenic 
character of ALR similar to HGF, because ALR does not only have pro-regenerative 
hepatotrophic effects but also seems to be regulated by similar cytokines. 
Furthermore, ALR is regulated only by factors such as cytokines which are known to 
initiate the process of regeneration. Therefore besides mitogens, ALR is regulated by 
some upstream factors of the process of liver regeneration. 
ALR promoter analysis revealed binding sites for several transcription factors of 
which four of them, one in the first intron, have been found for FOXA2. FOXA2, a 
winged helix protein which belongs to the Forkhead box (FOX) class of monomeric 
transcription factor 159, was shown to be mainly expressed in liver and gut regulating 
a number of hepatocyte-specific genes 93,160. Furthermore, using cDNA array 
V. Discussion 88 
expression analysis, FOXA2 has been identified as one of several genes which are 
consistently upregulated in livers from patients with HCC 99 and during liver 
regeneration after hepatectomy 98. In addition, using a transgenic mouse model for 
FOXA2 high expression levels of ALR were found in the liver 100. Therefore, it is likely 
that FOXA2 may be involved in the regulation of ALR expression which could be 
confirmed in this thesis. We found a strong response to FOXA2 specifically in intronic 
promoter region suggesting the presence of FOXA2 response element within the first 
intron of ALR gene. The presence of potential binding sites for FOXA2 within introns 
have been described by several authors 142 and in case of ALR promoter we could 
show a functional binding of FOXA2 141 within the first intron (+276/+282 bp) of ALR 
gene. As reported above ALR promoter was shown to be sensitive to IL-6 treatment 
and the underlying IL-6 response element is also located in the first intron 
(+255/+261 bp) in the proximity of FOXA2 and C/EBPβ binding sites. IL-6 RE was 
demonstrated to be required for a correct positioning of FOXA2 and C/EBPβ 161, 
another transcription factor which has been found to mediate IL-6 response of many 
hepatic genes 147,161,162. Therefore, analyzing ALR gene response to IL-6 we have 
focused on IL-6 RE and the binding sites of FOXA2 and C/EBPβ located in the first 
intron of ALR gene. 
First, we found no binding of IL-6 RE binding protein and C/EBPβ to their binding 
sites suggesting that these regulatory elements may not be involved in the IL-6 
response of ALR promoter. Second, we could demonstrate that FOXA2 binding to 
ALR promoter is stronger after treatment with IL-6 indicating a putative positive 
involvement of IL-6 RE-BP on FOXA2 binding to the promoter. FOXA transcription 
factors are regulators of genes important in inflammation 161,163-165 and 
development 166-170, and are regulated at the transcriptional level 148. It is worthwhile 
to mention that both C/EBPβ and C/EBPγ proteins have been shown to get activated 
by both cytokines IL-1 and IL-6 and further to induce the gene expression of 
FOXA2 148,171. Therefore we suggest that IL-6 induces the activity of ALR promoter 
by two possible mechanisms. First, IL-6 activates C/EBPβ increasing the gene 
expression of FOXA2 which in turn transactivates ALR promoter. Second, IL-6 
activates IL-6 RE-BP which may interacts with FOXA2 augmenting its binding to ALR 
promoter. In both cases, activation of ALR promoter leads to enhanced protein 
expression of ALR upon IL-6 treatment (Fig. 38). 
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Fig. 38: Schematic drawing of ALR promoter regulation. The first intron of ALR gene exhibits 
potential binding sites for IL-6 RE-BP, FOXA2 and C/EBPβ. Our studies showed that C/EBPβ 
could not bind to ALR promoter and therefore is not able to transactivate ALR promoter. 
However, activated C/EBPβ by IL-6 may induce the expression of FOXA2 resulting in 
transactivation of ALR promoter. Another mechanism by which IL-6 induces ALR expression 
may be mediated by IL-6 RE-BP. We have demonstrated that upon treatment with IL-6, 
IL-6 RE-BP could not bind to IL-6 RE located in the proximity of FOXA2 response element. 
This finding suggests that IL-6 RE-BP may interact with FOXA2 augmenting its binding to 
ALR promoter. Transcription factors are shown in oval and transcription factor binding sites 
are shown in frames. 
In addition to FOXA2, IL-6 RE-BP and C/EBPβ, we also identified potential binding 
sites for SP1 and HNF-4α. SP1 is a member of a huge family which binds to and acts 
through the GC box (GC-rich sequence) 172 and has been shown to be involved in 
the basal expression of TATA-less promoters 173. It was found that SP1 functions as 
an essential transcriptional activator of basal expression of ALR 88. Further, they 
found an HNF-4α binding site (DR-1) within the human ALR promoter and reported 
that HNF-4α could bind to this region and suppress the gene expression of human 
ALR 88. 
In our promoter study we further found other regulatory elements which could be 
involved in the regulation of ALR expression. We identified a perfect and nearly 
conserved antioxidant response element (ARE) in the promoter sequence of human 
ALR. ARE is a cis-acting sequence and has been found in the 5’-flanking region of 
many genes encoding phase II detoxifying enzymes including NAD(P)H: quinone 
reductase (NQO1), glutathione transferases (GSTs), heme oxygenase-1 (HO-1), 
aflatoxin B1 dehydrogenase and ferretin 174. Nuclear E2-factor related factor 2 (Nrf2), 
IL-6 RE-BP FOXA2 C/EBPβ
IL-6
ALR
FOXA2
IL-6 RE C/EBPβFOXA2 IL-6 RE
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a member of Cap’n’Collar family of basic region-leucine zipper transcription factors, 
was described to be an essential component of the ARE-binding transcriptional 
machinery 175. It has been demonstrated that Nrf2 translocates into the nucleus and 
binds cooperatively to the ARE with small MAF proteins after activation by 
redox/oxidative stress. The Nrf2 and target genes have been shown to be essential 
for protection against oxidative stress caused by chemical-induced cellular damage 
to the liver 176,177. Based on these findings we may speculate about a putative role of 
ALR as a hepatoprotective factor against oxidative stress caused by different insults 
such as chemical-induced liver injury. This assumption is underlined by reports which 
demonstrated several Nrf2 regulated protective proteins including ALR by microarray 
analysis 178,179. Taken together, the existence of an ARE within ALR promoter and 
the Nrf2 dependent-increase in the gene expression of ALR transcripts show 
evidence that Nrf2 may be involved in the regulation of ALR expression. 
ALR was shown to be upregulated under circumstances of liver regeneration, but 
less is known about its impact on cellular growth and potential tumorigenicity. Using 
an ALR-overexpressing hepatoma cell line we could not detect an altered 
proliferation rate in vitro, but rather an enhanced ability to adherence compared to 
wild type hepatoma cells. This was confirmed by in vivo growth studies of these cells 
demonstrating a more epithelial-like growth of ALR-expressing xenografts compared 
to a more tumorigenic and necrotic growth of wt-HepG2 xenografts. These findings 
prompted us to elucidate the molecular link between ALR overexpression and 
tumorgenetic features like altered adherence and cell motility. Metastasis (Greek: 
The change in the state) occurs in a series of multiple steps including tumor cell 
migration, invasion and proliferation 113,114, and is a main cause of human cancer 
deaths 111,112. Performing migration and invasion assays we found that increased 
levels of ALR reduced hepatoma cell motility diminishing migratory and invasive 
potential of hepatoma cells. This observation is underlined by an immunohistological 
study on human HCC samples which showed that high levels of ALR in HCC tissues 
are inversely correlated with the angioinvasion of hepatocellular carcinoma. Both 
migration and invasion are necessary for tumor growth and metastasis, and are part 
of a process called EMT 180. Epithelial-mesenchymal transition (EMT) is an 
orchestrated series of events in which cell-cell and cell-extracellular matrix (ECM) 
interactions are altered, the cytoskeleton is reorganized to confer the ability to move 
through a three-dimensional ECM, and a new transcriptional program is induced to 
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gain a mesenchymal phenotype 181. A prominent marker of EMT is the cell adhesion 
molecule E-cadherin, member of the family of Ca2+-dependent cadherins which 
mediate homotypic interaction between adjacent epithelial cells. Downregulation or a 
complete shutdown of E-cadherin expression have been observed in carcinoma 
cells 115,182 and in human tumors, while loss of E-cadherin-mediated cell adhesion 
correlates with the loss of epithelial morphology and with the acquisition of metastatic 
potential 183. Importantly, we demonstrate in this thesis that ALR-overexpressing 
hepatoma cells exhibit induced protein expression of E-cadherin which could not be 
detecetd in wild type hepatoma cells. Therefore, we conclude that increased levels of 
ALR recovers the expression of E-cadherin allowing for greater cell–cell adhesion 
and decreased cell motility. In order to analyze the mechanism by which ALR 
regulates E-cadherin, we analyzed if ALR may regulate factors upstream of 
E-cadherin such as SNAIL and HIF-1α or proteases known to cleave E-cadherin like 
MMP-3. SNAIL, a member of the SNAIL superfamily of zinc-finger transcriptional 
factors, has been shown to promote key steps in tumorigenesis 116,184 converting 
epithelial cells into mesenchymal cells by repressing E-cadherin expression 116 
(Fig. 39) 185. The hypoxia-inducible factor (HIF-1α) has been reported to be 
necessary and sufficient to suppress E-cadherin expression by inducing the 
expression of transcriptional repressors of E-cadherin 117,118. Another feature of EMT 
is the over-expression and/or activation of the matrix metalloproteinases (MMPs), 
which are involved in tumor invasion, angiogenesis and metastasis. Among them, 
MMP-3 (stromelysin-1, Str-1), exerts oncogenic effects and plays an important role 
by triggering EMT in vitro 119 and in vivo 120. It was reported further that MMP-3 can 
degrade the extracellular matrix (ECM) and activate other MMPs like MMP-1, MMP-9 
and MMP-13 186,187. MMP-1 was shown to be involved in the progression of human 
malignancies by promoting invasion and tumor growth in the metastatic process 121. It 
was shown that MMP-3 reduces E-cadherin by cleaving the E-cadherin protein on 
the cell membrane 119 and transcriptionally by inducing SNAIL expression via 
smad 2,3/4 122,188-191. In our study we found that ALR expression in hepatoma cells 
down-regulates SNAIL expression, while no effect on HIF-1α stability was observed, 
the second important regulating transcription factor of E-cadherin. In addition we 
found decreased levels of MMP-1 and MMP-3 in ALR expressing cells compared to 
wild type hepatoma cells. Therefore, the observed upregulation of E-cadherin may be 
explained either by modulating Smad/SNAIL or by MMP-3 pathways and include a 
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possible crosstalk/interaction of these cascades (Fig. 39). ZO-1 (Zona Occludens-1), 
a tight junction associated protein has been found to play an important role in cell-cell 
contact. ZO-1 shuttles between the plasma membrane and the nucleus or the cytosol 
and this cytoplasmic/nuclear relocalization has been shown to be involved in EMT 
and tumor invasion 192. We observed that ALR-overexpressing hepatoma cells exhibit 
high levels of ZO-1 which was mainly localized in the cytosol increasing cell-cell 
contact and decreasing cell motility (data not shown). Results presented in this thesis 
underline a suggested role of ALR in regulating EMT. 
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Fig. 39: Schematic drawing demonstrating the influence of ALR on EMT. ALR reduces the 
ECM deposition by decreasing TIMP-1 expression 83. In addition, ALR supports the epithelial 
phenotype by reducing MMP-3 and MMP-1 expression resulting in enhanced E-cadherin 
levels. Furthermore, ALR enhances the expression of MMP-9 triggering the myofibroblast 
cell death. Results demonstrated in this thesis are shown in frames. Dashed lines include 
several steps. 
Previous studies have provided evidence that ALR has a hepatoprotective effect on 
fibrogenesis because exogenously applied ALR ameliorated hepatic damage and 
decreased the degree of hepatic fibrosis induced by toxins such as CCl4/Ethanol, 
thioacetamide or porcine serum 84,193,194. While two studies have described the anti-
fibrotic effect of ALR to inhibit collagen deposition 193 or to decrease gene and protein 
expression of TIMP-1 (inhibitor of MMPs) 84, little is known regarding the underlying 
mechanism. Additionally, we have found that treatment of primary human 
hepatocytes with ALR decreased pro-fibrogenic gene expression of collagen type 1, 
IL-8, TIMP-1 and TGF-β (data not shown). Our preliminary in vitro data might parallel 
in vivo results 83,84 demonstrating that ALR ameliorates the hepatic fibrosis by 
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decreasing markers which are known to be involved in the initiation/progression of 
liver fibrosis such as TGF-β, collagen type 1 and TIMP-1 195-199. The repression of 
pro-fibrogenic gene expression as well as reversion of an EMT process by ALR 
renders this protein as an interesting candidate for anti-fibrotic therapy. 
Hepatic fibrosis is a wound-healing process in the liver caused by acute and chronic 
injury and characterized by an excess production and deposition of extracellular 
matrix components. Recently, in many models of experimental fibrosis, it has been 
reported that administration of HGF resulted in reduced tissue damage and fibrosis in 
the liver 200-205. HGF abrogates the expression of collagen type 1 as well as 
fibronectin and upregulates cell adhesion proteins such as E-cadherin and ZO-1 
resulting in a reversion of EMT 206. Further, HGF has been shown to induce MMP-9-
dependent myofibroblast cell death and thereby to reduce pulmonary fibrosis 207. In 
addition, HGF blocks bile duct EMT in a model of bile duct ligation and ameliorates 
the hepatic fibrotic lesions by reducing the expression of α-smooth muscle actin, 
attenuation of collagen type 1, 3 deposition and supressing the expression of 
TGF-β 200. Recent publications have demonstrated that HGF and ALR share several 
similarities like activating proliferative pathways such as MAPK cascade 11,12,14,26,64,77, 
high expression rate in liver diseases e.g. cirrhosis and hepatocellular 
carcinoma 67,81,134-136,208 and modulation of hepatic metabolism 76,209. The new data in 
this thesis may add another common feature of HGF and ALR acting as an anti-
fibrotic proteins attenuating fibrogenesis or even reversing fibrosis. Despite the 
possible application of HGF as a potent therapeutic agent with anti-cirrhotic 204,205, 
and anti-neoplastic 210 effects as well as supporting of liver regeneration 211,212, HGF 
remains an almost unspecific growth factor. In contrast, ALR seems to be a 
promising hepatotrophic drug with anti-cirrhotic, anti-fibrotic 83 and anti-metastatic 
effects restricted to the liver due to its high organ specifity. In this regard, our findings 
underscore that the blockade of EMT by ALR presents a novel strategy for 
prevention/reversion of hepatic fibrosis protecting the liver tissues from developing 
HCC. 
After analyzing the expression levels of ALR in regenerating livers as well as in 
human liver tumors, there are still some unanswered questions such as whether ALR 
expression is also regulated in other organs with regenerative capacity like muscle 
and intestine. At the protein level, the finding that the transcript of ALR is rapidly 
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induced by FOXA2 and IL-6, paves the way to future to determine whether 
anti-proliferative factors like TGF-β or IL-10 may reduce the expression of ALR not 
only in hepatocytes but also in non-parenchymal cells such as hepatic stellate cells 
and Kupffer cells. 
The cellular mechanism underlying the ALR-mediated prevention/reversion of hepatic 
fibrosis is still not completely understood. However, our findings presented in this 
thesis that ALR attenuates EMT progression in vitro, encouraged us to establish an 
Adv5/ALR virus which can be further used in different experimental fibrosis models. 
This tool would help to uncover the molecular mechanism underlying the anti-fibrotic 
impact of ALR by investigating the expression of several proteins known to be 
involved in both fibrolysis and fibrogenesis. More specifically, we would investigate 
whether ALR application influences the expression of TGF-β, collagen type 1 and 3, 
α-smooth muscle actin and the activation of Smads. Furthermore, application of ALR 
in experimental tumor models would help us to clarify the molecular background of 
the anti-metastatic effect of ALR. In details, it would be very interesting to analyze the 
expression and/or localization of various proteins which are involved in the process of 
metastasis such as cell-surface markers (E-cadherin, ZO-1), cytoskeletal markers 
(β-catenin, cytokeratin), ECM proteins (fibronectin, laminin) and transcription factors 
(SNAIL, SLUG and Twist). Additionally this approach, when coupled to microarray 
gene expression analysis, may help to gain more insight into ALR association in 
other cellualr processes such as inflammation, redox homeostasis as well as lipid 
metabolism and to identify genes which could be potentially regulated by ALR. 
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Liver regeneration is a multistep and well-orchestrated process which is initiated by 
injuries like tissue loss, infectious or toxic insults. It has been shown that expression 
of the hepatotrophic factor “Augmenter of Liver Regeneration” (ALR) is increased 
within liver regeneration as well as in liver diseases like cirrhosis and liver carcinoma. 
The aim of this thesis was to analyze how ALR is expressed, regulated and what 
impact an altered expression of ALR might have on the liver. Therefore, we 
investigated the expression of ALR in experimental models of liver injury which 
resemble hepatic patho-physiological disorders such as liver fibrosis and non-
alcoholic steatohepatitis. ALR mRNA expression could be shown to be upregulated 
independent of different insults and is increased in HCC tissues compared to normal 
tissues. Furthermore, our results showed that IL-6 rapidly induces the mRNA 
expression and protein level of ALR in human hepatocytes and hepatoma cells, 
whereas IL-1β reduces the expression levels of ALR. No changes in ALR levels 
could be observed after stimulation with growth factors suggesting that ALR is 
regulated only by factors which are known to initiate the process of regeneration. 
Furthermore, we analyzed the promoter sequence of ALR and identified putative 
regulatory elements for FOXA2, IL-6 RE-BP and C/EBPβ. Using luciferase assays 
and EMSA, we demonstrated that both IL-6 RE-BP and C/EBPβ could not 
transactivate/bind to the ALR promoter. In contrast, FOXA2 has been found to 
regulate the expression of ALR, and this regulation was amplified by simultaneously 
activation using IL-6. Additionally, ALR promoter exhibits a nearly conserved Nrf2 
binding site underlining a hepatoprotective function of ALR against oxidative stress. 
Using ALR-overexpressing HepG2 cells we could not detect an altered proliferation 
rate neither in vitro nor in vivo. ALR-overexpressing cells displayed an enhanced 
acquirement to adhere and a significant lower ability to migrate and invade compared 
to wild type cells. This finding is underlined by an immunohistochemical study which 
revealed that ALR expression in HCC is inversely correlated with tumor grading and 
angioinvasion. Furthermore, we demonstrated that ALR expression induces the 
expression of the adhesion molecule E-cadherin and reduces the expression of 
MMP-3 and SNAIL explaining the modulation of E-cadherin by ALR. In conclusion, 
this thesis was shown that ALR plays a role in hepatic regeneration independent of 
its cause and is regulated by upstream factors of liver regeneration like cytokines. 
Addionally, it was demonstrated that ALR expression counteracts the epithelial 
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mesenchymal transition (EMT) suggesting that application of ALR represents a 
promising therapeutical strategy for diseases in which EMT is involved. 
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AhR Aryl hydrocarbon receptor 
ALR Augmenter of liver regeneration 
ALR-R Augmenter of liver regeneration receptor 
AP-1 Activator protein-1 
APAAP Alkaline Phosphatase-Anti-Alkaline Phosphatase 
BDL Bile duct ligation 
BLAST Basic Local Alignment Search Tool 
bp Base pair 
CAR Constitutive androstane receptor 
CCl4 Carbon tetrachloride 
CDH1 E-cadherin 
cDNA Complementary DNA 
cis-acting acting from the same molecule 
Col-1 Collagen type I 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl Sulfoxyde 
DNA Deoxyribonucleic Acid 
dNTP Deoxinucleotide Triphosphate 
DTT Dithiothreitol 
E-cadherin Epithelial cadherin 
ECL Enhanced Chemiluminescence 
ECM Extracellular matrix 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic Acid 
e.g. “for example” 
EGF Epidermal growth factor 
EGF-R Epidermal growth factor receptor 
EMSA Electrophoretic mobility shift assay 
EMT Epithelial mesenchymal transition 
ERK Extracellular signal regulated protein kinase 
ERV1 Essential for respiration and vegetative growth 1 
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et al. “and others” 
FAD Flavin adenin dinucleotide 
FC Fold change 
FOXA2 Forkhead box A2 
g Gram; Gravitational force 
G-418 Geneticin 
h Hour 
HCC Hepatocellular carcinoma 
HGF Hepatocyte growth factor 
HIF Hypoxia-inducible factor 
HNF Hepatocyte nuclear factor 
HPO Hepatopoietin 
HSS Hepatic stimulator substance 
i.e. “that is” 
IFN-γ Interferon γ 
IGF Insulin-like growth factor 
IL Interleukin 
IL-6 RE-BP Interleukin-6 response element binding protein 
in vitro  lat.: „within the glass” 
in vivo  lat.: „within the living” 
JAB c-Jun activation domain-binding protein 
k Kilo 
kb Kilo base  
KC Kupffer cell 
kDa Kilo-Dalton 
KGF Keratinocyte growth factor 
L Liter 
LETF Liver-enriched transcription factor 
LPS Lipo polysaccharide 
LR Liver regeneration 
m Milli (10-3) 
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M Molar 
μ Mikro (10-6) 
mA Milliampere 
MCD Methionine-choline deficient 
MEK Kinase MAP Kinase Kinase 
MEKK1/2 MAP Kinase Kinase 1/2 
min Minute 
MMP Matrix metalloproteinase 
mRNA Messenger RNA 
mt-DNA Mitochondrial DNA 
mt-TFA Mitochondrial Transcription Factor A 
n Nano (10-9) 
NASH Non-alcoholic steatohepatitis 
Neo Neomycin 
NF-кB Nuclear factor of kappa light chain gene enhancer in B-cells 
nm Nanometer 
NASH Non-alcoholic steatohepatitis 
NP-40 Nonidet P-40 
NPC Non-parenchymal cell 
nt Nucleotide 
OD Optical density 
ODC Ornithine decarboxylase 
p Pico (10-12) 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDGF Plateled-derived growth factor 
PH Partial hepatectomy 
PVDF Polyvinylidenfluorid 
PXR Pregnane X receptor 
qRT-PCR Quantitative Real-Time PCR 
RLU Relative luciferase unit 
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RNA Ribonucleic acid 
RNase Ribonuclease 
ROS Reactive oxygen species 
rpm Rounds per minute 
rRNA Ribosomal RNA 
RT Room Temperature 
SD Standard deviation 
SDS Sodium Dodecyl Sulfate 
sec Second 
siRNA Small interference RNA 
SP1 Stimulating protein 1 
STAT Signal transducers and activators of transcription 
TEMED N,N,N’,N’,-Tetramethylenediamine 
TF Transcription factor 
TFIIB Transcription factor B of Pol II 
TGF-α Transforming growth factor α 
TGF-β Transforming growth factor β 
TIMP Tissue inhibitor of metalloproteinase 
TNF-α Tumor necrosis factor α 
trans-acting acting from a different molecule 
U Unit 
via lat.: „By way of” 
WB Western Blot 
wt Wild type 
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Map of pcDNA3.1 vector (Invitrogen) 
 
The figure below summarizes the features of the pcDNA3.1 (+) and pcDNA3.1 (-) 
vectors. Into pcDNA3.1(+) vector ALR cDNA was subcloned to generate the stable 
ALR-overexpressing HepG2 cells. 
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Map of pGL2-Basic vector (Promega) 
 
The figure below summarizes the features of the pGL2-Basic vector. The 
promoterless pGL2-Basic vector was used to perform the Luciferase Reporter gene 
Assays. 
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von mir weder unmittelbar noch mittelbar geldwerte Leistungen für Arbeiten erhalten, 
die im Zusammenhang mit dem Inhalt der vorliegenden Dissertation stehen. 
 
Die Arbeit wurde bisher weder im In- noch im Ausland in gleicher oder ähnlicher 
Form einer anderen Prüfungsbehörde vorgelegt. 
 
Ich versichere an Eides statt, dass ich nach bestem Wissen die reine Wahrheit 
gesagt und nichts verschwiegen habe. 
 
Vor Aufnahme der obigen Versicherung an Eides statt wurde ich über die Bedeutung 
der eidesstattlichen Versicherung und die strafrechtlichen Folgen einer unrichtigen 
oder unvollständigen eidesstattlichen Versicherung belehrt. 
 
 
 
 
 
 
 
Regensburg, den 25.05.2009         Rania Dayoub 
